

## Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015

Masamichi Yokoe · Tadahiro Takada · Toshihiko Mayumi · Masahiro Yoshida · Shuji Isaji · Keita Wada · Takao Itoi · Naohiro Sata · Toshifumi Gabata · Hisato Igarashi · Keisho Kataoka · Masahiko Hirota · Masumi Kadoya · Nobuya Kitamura · Yasutoshi Kimura · Seiki Kiriyama · Kunihiro Shirai · Takayuki Hattori · Kazunori Takeda · Yoshifumi Takeyama · Morihisa Hirota · Miho Sekimoto · Satoru Shikata · Shinju Arata · Koichi Hirata

Published online: 13 May 2015

© 2015 Japanese Society of Hepato-Biliary-Pancreatic Surgery

The author's affiliations are listed in the Appendix.

Correspondence to:  
Toshihiko Mayumi, Department of Emergency Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 807-8555, Japan  
e-mail: mtoshi@med.uoeh-u.ac.jp

DOI: 10.1002/jhbp.259

### Abstract

**Background** Japanese (JPN) guidelines for the management of acute pancreatitis were published in 2006. The severity assessment criteria for acute pancreatitis were later revised by the Japanese Ministry of Health, Labour and Welfare (MHLW) in 2008, leading to their publication as the JPN Guidelines 2010. Following the 2012 revision of the Atlanta Classifications of Acute Pancreatitis, in which the classifications of regional complications of pancreatitis were revised, the development of a minimally invasive method for local complications of pancreatitis spread, and emerging evidence was gathered and revised into the JPN Guidelines.

**Methods** A comprehensive evaluation was carried out on the evidence for epidemiology, diagnosis, severity, treatment, post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and clinical indicators, based on the concepts of the GRADE system (Grading of Recommendations Assessment, Development and Evaluation). With the graded recommendations, where the evidence was unclear, Meta-Analysis team for JPN Guidelines 2015 conducted an additional new meta-analysis, the results of which were included in the guidelines.

**Results** Thirty-nine questions were prepared in 17 subject areas, for which 43 recommendations were made. The 17 subject areas were: Diagnosis, Diagnostic imaging, Etiology, Severity assessment, Transfer indication, Fluid therapy, Nasogastric tube, Pain control, Antibiotics prophylaxis, Protease inhibitor, Nutritional support, Intensive care, management of Biliary Pancreatitis, management of Abdominal Compartment Syndrome, Interventions for the local complications, Post-ERCP pancreatitis and Clinical Indicator (Pancreatitis Bundles 2015). Meta-analysis was conducted in the following four subject areas based on randomized controlled trials: (1) prophylactic antibiotics use; (2) prophylactic pancreatic stent placement for the prevention of post-ERCP pancreatitis; (3) prophylactic non-steroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP pancreatitis; and (4) peritoneal lavage. Using the results of the meta-analysis, recommendations were graded to create useful information. In addition, a mobile application was developed, which made it possible to diagnose, assess severity and check pancreatitis bundles.

**Conclusions** The JPN Guidelines 2015 were prepared using the most up-to-date methods, and including the latest recommended medical treatments, and we are confident that this will make them easy for many clinicians to use, and will provide a useful tool in the decision-making process for the treatment of patients, and optimal medical support. The free mobile application and calculator for the JPN Guidelines 2015 is available via <http://www.jshbps.jp/en/guideline/jpn-guideline2015.html>

**Keywords** Acute pancreatitis · Antibiotics · Bundles · Diagnosis · Guidelines · Intensive care · Nutrition · Pancreas · Post-ERCP pancreatitis · Severity assessment · Surgery

## Introduction

The Japanese (JPN) Guidelines for the management of acute pancreatitis were published in the *Journal of Hepato-Biliary-Pancreatic Surgery* in 2006, as evidence-based guidelines consisting of nine original papers [1–9]. They were then revised in 2010, including pancreatitis bundles as clinical indicators [10–20].

In 2012 the classification of localized complications of pancreatitis was revised in the Atlanta Classifications [21], and at the same time, minimally invasive surgeries such as interventional endoscopy (IVE), and interventional radiology (IVR) were advanced. Further, the definitions of treatment guidelines were revised in 2011 and the GRADE system (Grading of Recommendations Assessment, Development and Evaluation) [22–43] was adopted in this revision, leading to the development of guidelines, which are applied closer to the site of treatment and which better consider the benefits and risks to patients.

## Methods

### Scope/purpose

The purpose of these guidelines remains the same as that of the JPN Guidelines (2006) [1–9], and the JPN Guidelines 2010 [10–20], namely to provide practical medical guidelines for clinicians treating acute pancreatitis, to assist general clinicians to quickly determine the severity of acute pancreatitis and take effective and appropriate medical treatments for the patients with acute pancreatitis.

### Stakeholder involvement

Members of the Revision Committee of JPN Guidelines 2015 included gastroenterologists, surgeons, emergency physicians, radiologists, and endoscopists etc., and the guidelines were then evaluated by a wide range of external parties, including the general public, attorneys, internal medicine physicians and surgeons.

These guidelines are designed to be used by all physicians who treat acute pancreatitis, ranging from general clinicians to physicians that specialize in severe acute pancreatitis.

### Guideline preparation method

#### *CQ preparation and literature search*

Members of the Revision Committee of JPN Guidelines 2015 reviewed the Clinical Questions (CQ) used in the JPN Guidelines (2006) and JPN Guidelines 2010, based on the important

clinical issues listed under the Scope, and then prepared new CQ where needed. Keywords were extracted from the CQ, and academic papers were collected. The MEDLINE, Cochrane Library databases and *Japana Centra Revuo Medicina Web* were used for this. In addition to a systematic search using the JPN Guidelines 2010, papers published from September 2008 to April 2014 were searched, and papers published outside of this period were treated as being outside of the scope of the search period.

#### *Method of systematic literature review*

Evidence assessment was performed following the procedures described below (Table 1).

- (1) Extraction of risk/benefit outcomes from the CQ
- (2) Evaluation of each paper: Preparation of structured abstracts  
The information in each article was summarized, including the study design, and the risk of bias in the randomized controlled trials (RCTs) and observational studies was determined.
- (3) Method of defining the quality of evidence supporting recommendations

**Table 1** Quality of evidence

Comprehensive assessment of stored multiple papers by outcomes and design.
(1) Initial assessment: Assessment by each study design group A: SR (systematic review), MA (meta-analysis), RCT (randomized controlled trial) C: OS (observational study) D: CS (case series, case report)
(2) Assessment of the presence/absence of factors which decrease evidence levels <ul style="list-style-type: none"> <li>• Risk of bias in study quality</li> <li>• Inconsistent results (different conclusions by various papers)</li> <li>• Indirect evidence (inconsistency between content within a paper and CQ, or content in a paper which is not directly applicable to clinical use)</li> <li>• Inaccurate data (insufficient number of cases)</li> <li>• High probability of publication bias (only favorable results reported)</li> </ul>
(3) Assessment of the presence/absence of factors which increase evidence levels <ul style="list-style-type: none"> <li>• Profound effects with no confounders (profound effects expected for all cases)</li> <li>• Dose-response gradient (more profound effects expected with increased dosage)</li> <li>• Possible confounders which diminish actual effects</li> </ul>
Comprehensive assessment: The final quality of evidence was assessed and graded as A, B, C, D

A comprehensive evaluation of the evidence was carried out using the GRADE system [22–43] and each of the papers evaluated in (2) were evaluated in relation to each of the outcomes presented in (1) above.

### Grading the strength of recommendations

The strength of recommendations was graded with reference to (1) the quality of the evidence, (2) the preferences of the patient, (3) risks and benefits and (4) cost estimates, etc. In terms of consensus-building, a vote was taken using the Delphi method and nominal group technique (NGT) method, and issues with a support rate of more than 70% were approved.

The grading of recommendations was divided into two categories, “1: Strong Recommendations” and “2: Weak Recommendations” which are described, respectively, as “recommendations” and “suggestions.”

### Meta-analysis

The Meta-Analysis team for JPN Guidelines 2015 conducted a new meta-analysis of four subjects of study using the evidence obtained in the preparation of the guidelines, and used the results for the grading of recommendations.

- (1) prophylactic antibiotics use [44]
- (2) prophylactic pancreatic stent placement for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis
- (3) prophylactic non-steroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP pancreatitis
- (4) peritoneal lavage (PL)

### Results

Thirty-nine questions were prepared in 17 subject areas, for which 43 recommendations were made (Table 2).

### Diagnosis

*CQ1 Which pancreatic enzyme measurements are important when diagnosing acute pancreatitis?*

The measurement of serum lipase is recommended for the diagnosis of acute pancreatitis.

However, when the measurement of lipase is difficult, serum amylase (pancreatic amylase) should be measured.

#### (1B)

<Comment> The detection of elevated levels of blood pancreatic enzymes is crucial in the diagnosis of acute

pancreatitis [4, 13, 21, 45–52]. When the diagnosis acute pancreatitis cannot be differentiated from other diseases, serum lipase is superior to any other pancreatic enzymes, including serum amylase [53] (Table 3).

*CQ2 Is a urinary trypsinogen-2 dipstick useful in diagnosing acute pancreatitis?*

Urinary trypsinogen-2 dipstick may be useful for minimally invasive method and rapid diagnosis of acute pancreatitis. However, this is not commercially available in Japan and therefore it cannot be recommended at this time.

#### (ungraded B)

<Comment> The diagnosis of acute pancreatitis using a urinary trypsinogen-2 dipstick is highly effective in medical institutions where a blood test cannot be examined, not requiring blood sample, given the short time (5 min) required for the test, its diagnostic ability, and the fact that it is roughly equivalent to serum pancreatic enzymes [54–56].

### Diagnostic imaging

*CQ3 Is ultrasonography recommended for the diagnosis of acute pancreatitis?*

When acute pancreatitis is suspected, ultrasonography is recommended.

#### (1C)

<Comment> Ultrasonography, which enables the visualization of findings associated with acute pancreatitis such as pancreatic enlargement and inflammatory changes around the pancreas, is useful in diagnosing acute pancreatitis [57, 58]. It can also visualize causes and abnormal findings associated with the pathological conditions of acute pancreatitis such as ascites, bile duct stones and bile duct dilatation (Fig. 1). Color Doppler ultrasonography is useful in the diagnosis of pseudoaneurysm developing inside the pseudocyst [59].

*CQ4 Is computed tomography (CT) recommended in the diagnosis of acute pancreatitis?*

CT is recommended for the diagnosis of acute pancreatitis.

#### (1C)

<Comment> When a definitive diagnosis of acute pancreatitis is not possible based on clinical findings, blood/urine tests or ultrasonography, or where the etiology of pancreatitis is uncertain, contrast-enhanced dynamic CT should be actively used as long as no renal function problems are observed. Particularly in acute pancreatitis caused by pancreatic ductal stenosis due to pancreas tumors such as cancer, a simple CT alone is very likely to overlook the causative pancreatic cancer [60–62].

**Table 2** Summary of recommendation**A. Diagnosis**

1 The measurement of serum lipase is recommended for the diagnosis of acute pancreatitis. However, when the measurement of lipase is difficult, serum amylase (pancreatic amylase) should be measured. (1B)

2 Urinary trypsinogen-2 dipstick may be useful for minimally invasive method and rapid diagnosis of acute pancreatitis. However, this is not commercially available in Japan and therefore it cannot be recommended at this time. (ungraded B)

**B. Diagnostic imaging**

3 When acute pancreatitis is suspected, ultrasonography is recommended. (1C)

4 CT is recommended for the diagnosis of acute pancreatitis. (1C)

5 MRI is more useful than CT in diagnosing bile duct stones causing pancreatitis and hemorrhagic necrotizing pancreatitis. (2C)

6 Contrast-enhanced CT is useful for the diagnosis of active hemorrhage and thrombosis associated with pancreatitis. (1C)

**C. Etiology**

7 During etiological diagnosis, the diagnosis of gallstone-induced acute pancreatitis should be determined as the most important and urgent issue, as this greatly affects the treatment, such as whether endoscopic papillary treatment should be performed or not. (1A)

**D. Severity assessment**

8 In principle, it is recommended that a severity assessment be made immediately after diagnosis and repeated over time (especially within 48 h of the diagnosis). (1C)

9 It is recommended that a scoring system is used for severity assessments. (1B)

10 Contrast-enhanced CT is recommended for identifying poorly contrasted areas of acute pancreatitis and is also useful in the diagnosis of complications. However, the possibility of exacerbating pancreatitis and renal function and allergic reactions associated with the contrast must be considered. (2B)

**E. Transfer indication**

11 Severe cases should be treated immediately at a facility capable of providing treatment for severe acute pancreatitis. Where such treatment is difficult at the facility, it is strongly recommended that the consideration be given to the immediate transfer of the patient. Even where the case is mild in the early stages, severity assessments should be carried out repeatedly over time, and when the criteria are met, transfer should be considered. (1C)

**F. Fluid therapy**

12 An extracellular solution (Ringer's Lactate solution, etc.) is recommended as the initial infusion solution for acute pancreatitis. (1C)

13 For patients in shock or with dehydration in the early phases of acute pancreatitis, short-time rapid fluid resuscitation (150–600 mL/h: depending on the presence of shock and the dehydration level) is recommended. However, this should be carried out with great care in order to avoid excessive fluid infusion. For patients without dehydration, they should be monitored closely with an appropriate amount of fluid infusion (130–150 mL/h). Particularly for patients with comorbidities such as cardiac or renal failure, the circulating blood volume should be carefully evaluated to determine the rate of fluid infusion. (1C)

14 If a mean arterial pressure of 65 mmHg or more and a urine output of 0.5 mL/kg per h or more has been secured in patients with acute pancreatitis, rapid fluid infusion should be discontinued and a reduction of the rate of fluid infusion is suggested. The volume of infusion should be adjusted to maintain these levels. (2C)

**G. Nasogastric tube**

15 No remedial effect of nasogastric tube insertion has been observed for mild acute pancreatitis. Therefore, the routine use of nasogastric suction tubes is not required. (1A)

**H. Pain control**

16 Pain associated with acute pancreatitis is severe and persistent, raising the need of sufficient pain control. (1A)

**I. Antibiotics prophylaxis**

17 The prophylactic administration of antibiotics is not necessary in mild acute pancreatitis, since the incidence and mortality rates of infectious complications from mild acute pancreatitis are low. (1A)

The prophylactic administration of antibiotics in severe acute pancreatitis and necrotizing pancreatitis may improve the prognosis, if carried out in the early phases of pancreatitis (within 72 h of onset). (2B)

18 No remedial effect of the prophylactic administration of antifungal agents for acute pancreatitis has been observed. Therefore, routine administration is not recommended. (1C)

**J. Protease inhibitor**

19 The effectiveness of intravenous administration of protease inhibitor (gabexate mesilate) for improving the life prognosis and the rate of complications of acute pancreatitis has not been clearly proven. Further consideration of the efficacy of continuous high-dose intravenous administration for severe cases is required. (ungraded B)

**K. Nutritional support**

20 Intravenous hyperalimentation is not recommended for mild cases. (1B)

Total parenteral nutrition (not performed with oral or enteral nutrition) should be avoided if possible. (1B)

(Continues)

**Table 2** (Continued)

**21** In severe cases, it is more significant as a measure to prevent infection rather than as a route of nutrition support. It can be applied and implemented for severe cases which do not have accompanying intestinal complications. (1A)

**22** If initiated in the early phase, enteral nutrition can reduce the incidence of complications and can contribute to an increased rate of survival. Therefore, it is desirable that it be started within at least 48 h of admission. (2A)

**23** In principle, it is recommended that enteral feeding tubes be inserted into the jejunum through the Treitz ligament. However, if a feeding tube cannot be inserted into the jejunum, nutrients can be infused into the duodenum or stomach instead. (2B)

**24** The initiation of oral administration should be determined using indicators such as the subsidence of abdominal pain and the serum pancreatic enzyme (especially serum lipase) level, etc. (2B)

#### **L. Intensive care**

**25** No life-saving effect has been observed from peritoneal lavage for acute pancreatitis, and therefore it is not recommended. (2B)

**26** For severe cases where circulation dynamics are not stable with anuria even after sufficient initial fluid infusion or cases with abdominal compartment syndrome (ACS), CHF/CHDF should be introduced. (1C)

The efficacy of CHF/CHDF in cases of severe acute pancreatitis not mentioned above is uncertain. Therefore, routine use is not recommended. (2C)

**27** Continuous Regional Arterial Infusion therapy is reported to be effective in reducing pancreatic infection and mortality rates for severe acute pancreatitis and acute necrotizing pancreatitis, but its efficacy has not been confirmed. (ungraded B)

#### **M. Management of biliary pancreatitis**

**28** Early ERCP/ES should be performed in gallstone-induced acute pancreatitis when complications of cholangitis or prolonged passage disorder of the biliary tract are suspected. (1A)

**29** To prevent the recurrence of gallstone-induced acute pancreatitis, cholecystectomy is recommended for cases where such surgery is possible. (1B)

**30** A cholecystectomy should be performed as soon as gallstone-induced acute pancreatitis has been resolved. (1B)

#### **N. Management of abdominal compartment syndrome**

**31** The sequential measurement of IAP is recommended for cases with excessive fluid infusion, high severity, renal and respiratory complications, and fluid accumulation in multiple areas as observed by CT, since the onset of ACS increases the mortality rate in such cases. (2C)

**32** When there is persistent or recurrent  $IAP \geq 12$  mmHg, conservative treatment (gastrointestinal decompression, intra-abdominal decompression, improvement of abdominal wall compliance, appropriate fluid infusion and circulation management) should be initiated. The goal should be to manage for  $IAP \leq 15$  mmHg. Surgical decompression should be considered only when internal treatment is not effective for patients with  $IAP > 20$  mmHg and where the additional complication of organ failure is of concern. (2D)

#### **O. Interventions for the local complications**

**33** In principle, conservative treatment should first be performed for necrotizing pancreatitis. The best indication for intervention is applied to cases of infected pancreatic necrosis with suspected or confirmed infection accompanying an aggravated general condition. (1C)

**34** Infected pancreatic necrosis should be suspected when clinical symptoms and blood test findings deteriorate. Routine use of FNA is not required for diagnosis, and clinical signs and CT should be used for a comprehensive determination. If an aggravated general condition is observed, percutaneous drainage or endoscopic drainage should be given for diagnosis and treatment. (1C)

**35** If possible, therapeutic intervention for infected pancreatic necrosis should be performed after 4 weeks of onset, when the necrosis has been sufficiently walled off, or in other words, during WON period. (2C)

**36** During therapeutic intervention for infected pancreatic necrosis, percutaneous (retroperitoneal) drainage or endoscopic transluminal drainage should be first given, and if no improvement is achieved, necrosectomy should then be performed. Necrosectomy by endoscopic or retroperitoneal approach is recommended. (2B)

#### **P. Post-ERCP pancreatitis**

**37** Prophylactic temporary pancreatic stent placement is useful as an effective endoscopic procedure for the prevention of post-ERCP pancreatitis. This should only be performed in the high-risk groups\* for post-ERCP pancreatitis given the risks and cost. (2A)

The guidewire method is very likely to reduce the incidence of post-ERCP pancreatitis. (2A)

**38** For the prevention of post-ERCP pancreatitis, the intrarectal administration of NSAIDs should be carried out for all cases undergoing ERCP with no contraindications. (2A)

(Other drugs should not be used as routine preventive measures, since their efficacy has been refuted or is uncertain.)

#### **Q. Clinical indicators (Pancreatitis Bundles 2015)**

**39** A high rate of implementation of the pancreatitis bundles may contribute to improving prognosis of patients with severe acute pancreatitis. (1C)

*4–1: Can acute interstitial edematous pancreatitis be differentiated from acute necrotizing pancreatitis using imaging diagnosis?*

By referring to the non-contrast CT level and the imaging ability of contrast-enhanced CT for pancreas and

peripancreatic tissues, acute peripancreatic fluid collection (APFC) associated with edematous pancreatitis can be differentiated from acute necrotic collection (ANC) associated with necrotizing pancreatitis. This can be useful in determining a treatment strategy (Fig. 2).

(C)


**Table 3** JPN diagnostic criteria\*

1. Acute abdominal pain and tenderness in the upper abdomen.
2. Elevated levels of pancreatic enzymes in the blood or urine.
3. Abnormal findings of acute pancreatitis detected by US, CT or MRI.

Patients who present with at least two of the above three manifestations and in whom other pancreatic diseases and acute abdomen have been ruled out are diagnosed as having acute pancreatitis. However, acute aggravation in chronic pancreatitis should be included as the category of acute pancreatitis.

Note: Measurement of pancreatic enzymes (such as pancreatic amylase and lipase) with high specificity for the pancreas is desirable.

\* The diagnostic criteria of acute pancreatitis was established by the Japanese Ministry of Health, Labour, and Welfare 2008 Cited from Ref. [13]



**Fig. 1** Ultrasonography. Mild pancreatic enlargement and fluid accumulation in the anterior pararenal space, transverse mesocolon and bursa omentalis can be observed

<Comment> The differentiation of acute necrotizing pancreatitis from acute edematous pancreatitis is important in determining the treatment strategy. The evaluation of acute edematous pancreatitis and acute necrotizing pancreatitis is difficult with the non-contrast CT, and thus an angiographic evaluation of the pancreas using contrast-enhanced dynamic CT is needed [21, 63]. In many cases of early-onset pancreatitis (less than 1 week), the differentiation of acute peripancreatic fluid collection (APFC) associated with edematous pancreatitis from acute necrotic collection (ANC) can be difficult. In the early phases of acute pancreatitis, the poorly defined pancreas in the arterial phase of dynamic CT imaging can be reversible ischemia, and cannot be conclusively identified as necrosis of the pancreatic parenchyma. However, necrotizing pancreatitis is strongly suspected if a poorly

contrasted area is observed by dynamic CT more than 2 weeks after onset [64] (Fig. 3).

*4–2: Can walled-off necrosis (WON) be differentiated from pancreatic pseudocyst (PPC) using imaging diagnosis?*

By referring to the shape, extent and internal characteristics (CT contrast level and magnetic resonance imaging (MRI) signal intensity), PPC and WON can be differentiated. This can be useful in determining a treatment regime.

(C)

<Comment> About 4 weeks after the onset of ANC, a capsule-like rim appears around the fatty necrotic focus, forming a shape called WON (Fig. 4). It is important to differentiate pseudocysts that form by encapsulating fluid collection due to edematous pancreatitis from WON that is formed by encapsulating necrotic substances due to necrotizing pancreatitis [63, 65]. WON has an irregular shape, and not only extends to peripancreatic tissues and mesocolon, but also to the paracolic gutter [63, 65, 66]. Inside WON, there is a mixture of fluid, necrotic substances and fat tissues, making the CT contrast level higher than water concentration and, in many cases, inhomogeneous. By referring to the shape, extent and internal characteristics (CT contrast level and MRI signal intensity), PPC and WON can be differentiated in many cases.

*CQ5 In which cases is MRI useful for the diagnosis of acute pancreatitis?*

MRI is more useful than CT in diagnosing bile duct stones causing pancreatitis and hemorrhagic necrotizing pancreatitis.

(2C)

<Comment> Although it can be difficult in some cases to differentiate parapancreatic fatty necrosis from fluid collection by CT, an MRI enables the clear differentiation of fatty necrosis from fluid based on the signal strength. Compared with fluid, fatty necrosis presents higher signals in T1-enhanced imaging and mildly lower signals in T2-enhanced imaging [67–69], and GdDTPA dynamic MRI imaging can depict the foci of necrotizing pancreatitis as a poorly contrasted area [70, 71].



*CQ6 Is contrast-enhanced CT useful for the diagnosis of vascular complication associated with acute pancreatitis?*

Contrast-enhanced CT is useful for the diagnosis of active hemorrhage and thrombosis associated with pancreatitis.

(1C)

<Comment> In acute pancreatitis, bleeding can occur in the areas from the peripancreatic tissues to the mesentery and mesocolon. Contrast-enhanced CT is necessary when there is a need to evaluate the presence of persistent bleeding

**Fig. 2** Acute necrotic collection (ANC). In non-contrast computed tomography (CT) (a), inhomogeneous fluid retention (indicated by the arrow) can be observed from the transverse mesocolon to the left paracolic gutter, accompanied with internal fat accumulation. Although it is poorly contrasted by contrast-enhanced CT (b), middle colic artery (MCA) running inside can be observed. This can be diagnosed as acute necrotic collection (ANC) in the transverse mesocolon



**Fig. 3** Classification of pancreatic fluid collection by the revised Atlanta classification. *APFC* acute peripancreatic fluid collection, *ANC* acute necrotic collection, *PPC* pancreatic pseudocyst, *WON* walled-off necrosis

[72]. Also, a peripancreatic arterial rupture can occur in acute pancreatitis, accompanied by acute peripancreatic fluid collection, causing internal bleeding (known as pseudoaneurysm) [73, 74] (Fig. 5). Contrast-enhanced CT and color Doppler ultrasonography is necessary to accurately diagnose venous thrombus [75].

**Etiology**

*CQ7 Which pathological conditions should be considered as priority issues during etiological diagnosis?*

During etiological diagnosis, the diagnosis of gallstone-induced acute pancreatitis should be determined as the most important and urgent issue, as this greatly affects the treatment, such as endoscopic papillary treatment.

**(1A)**

<Comment> Bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) values and an ultrasonography should be examined in all cases to diagnose the presence of gallstone-induced acute pancreatitis [76]. MRI/magnetic resonance cholangiopancreatography

(MRCP) can visualize common bile duct stones, an anomalous arrangement of pancreaticobiliary ducts, and pancreas divisum, and is useful for the etiological diagnosis of acute pancreatitis [77–79]. Endoscopic ultrasonography (EUS) has a better capacity for visualizing common bile duct stones compared to ultrasonography [80–82]. It can diagnose bile duct stones, chronic pancreatitis, pancreatic cancer and intraductal papillary mucinous tumor, and is useful for the etiological diagnosis of acute pancreatitis [83, 84].

**Severity assessment**

*CQ8 When should a severity assessment be performed?*

In principle, it is recommended that a severity assessment be made immediately after diagnosis and repeated over time (especially within 48 h of the diagnosis).


**(1C)**

<Comment> Severity assessments for acute pancreatitis are useful for the appropriate introduction of initial treatment, and, when necessary, transfer to facilities where treatment for severe acute pancreatitis can be provided [85–87]. A severity assessment at the time of the diagnosis of acute pancreatitis can increase the possibility of accurate treatment for the patient and an improved prognosis. Repeated severity assessments may be small in cost. Members of the Revision Committee of JPN Guidelines 2015 reached the consensus that sequentially repeated severity assessments are highly beneficial for patients. The revised edition of the Atlanta Classifications (2012) [21] also state that “the severity of acute pancreatitis can be reassessed on a daily basis while the pancreatitis is still evolving, and in particular re-evaluations should be made 24 h, 48 h and 7 days after admission to the hospital.”


*CQ9 Is a scoring system useful for severity assessments?*

It is recommended that a scoring system is used for severity assessments.

**Fig. 4** Acute necrotic collection (ANC) and walled-off necrosis (WON). In the non-contrast computed tomography (CT) (a) and contrast-enhanced CT (b), a high level of fluid concentration (\*) was observed around the enlarged pancreatic parenchyma, and acute necrotic collection (ANC) was suspected. In a non-contrast CT (c) and contrast-enhanced CT (d) carried out 4 weeks after onset, an enlarged necrosis was encapsulated (indicated by arrowheads) with an irregular shape. This was diagnosed as walled-off necrosis (WON) and a drainage operation was performed



**Fig. 5** Bleeding in acute pancreatitis. In the non-contrast computed tomography (CT) (a), hemorrhagic fat necrosis can be observed in the pancreas, peripancreatic tissues, lesser sac space and transverse mesocolon. High density areas (\*) can be partly observed, accompanied by a bleeding mass. In the dynamic CT (b), contrast agent leakage (pseudoaneurysm, indicated by the arrowheads) inside the bleeding mass can be observed, indicating persistent bleeding



### (1B)

<Comment> Various scoring systems have been proposed and are used at clinical sites for severity assessments of acute pancreatitis. The Ranson score [88] was reported in 1974, the Glasgow score [89] in 1984, the APACHE-II [87] in 1989, and the systemic inflammatory response syndrome (SIRS) [90] in 2006, all of which are used as scoring systems. In terms of new scoring systems, the Panc 3 score [91] and POP score [92] were proposed in 2007, the BiSAP score [93] in 2008, and the HAPS score [94] in 2009.

The JPN Severity Score (JSS) was revised in 2008 [14] (Table 4), and it has been reported that the best predictors of organ failure are the JSS and BiSAP scores [95]. Also, according to a report by Mounzer et al., in comparison to the Ranson, Glasgow, APACHE-II, SIRS, POP, BiSAP, JSS and HAPS scoring systems, the JSS had the best scoring capacity for AUC at 48 h after admission [96].

*CQ10 Is contrast-enhanced CT useful for severity assessments of acute pancreatitis that is suspected to increase in severity?*

(At facilities where treatment for acute pancreatitis is provided,) Contrast-enhanced CT is recommended for identifying poorly contrasted areas of acute pancreatitis and is also useful in the diagnosis of complications. However, the possibility of exacerbating pancreatitis and renal function and allergic reactions associated with the contrast must be considered.

### (2B)

<Comment> The presence of necrotizing pancreatitis and the extension of inflammatory changes are closely related to various complications and prognosis [97–99], and accurate diagnosis is necessary. The evaluation of an enlarged pancreas, inflammatory extension to

peripancreatic fat tissue, fluid collection, pseudocyst, and fat necrosis are generally possible with non-contrast CT. However, the diagnosis and evaluation of necrotizing pancreatitis and its scope needed for severity assessments is not possible with non-contrast CT, and contrast-enhanced CT is required for this [100] (Figs 6–8). If contrast-enhanced CT is taken within 4 to 10 days of onset, the diagnosis of necrotizing pancreatitis can be made with an accuracy of almost 100% [97, 98, 100, 101].

#### Transfer indication

*CQ11 When should patients with acute pancreatitis be transferred to specialized hospital?*

Severe cases should be treated immediately at a facility capable of providing treatment for severe acute pancreatitis. Where

such treatment is difficult at the facility, it is strongly recommended that the consideration be given to the immediate transfer of the patient. Even where the case is mild in the early stages, severity assessments should be carried out repeatedly over time, and when the criteria are met, transfer should be considered.

#### (1C)

<Comment> It has been reported that hospitals with a large number of cases of acute pancreatitis have good clinical outcomes [102–104]. According to a report by Murata et al. using Japan's Diagnosis Procedure Combination (DPC)\* data, good clinical outcomes were achieved in hospitals receiving a large number of patients annually [103].

For cases considered “severe” according to the JSS, patients should be transferred to a facility where ICU management, IVR, continuous hemodiafiltration (CHDF), endoscopic treatment for cholelithiasis, surgical treatment, a

**Table 4** JPN Severity Score (JSS)

The severity scoring system of acute pancreatitis of the Japanese Ministry of Health, Labour and Welfare (2008)

Prognostic factors (1 point for each factor)

1. Base excess  $\leq -3$  mEq/L or shock (systolic blood pressure  $< 80$  mmHg)
2. PaO<sub>2</sub>  $\leq 60$  mmHg (room air) or respiratory failure (respirator management is needed)
3. BUN  $\geq 40$  mg/dL (or Cr  $\geq 2.0$  mg/dL) or oliguria (daily urine output  $< 400$  mL even after IV fluid resuscitation)
4. LDH  $\geq 2$  times of upper limit of normal
5. Platelet count  $\leq 100,000/\text{mm}^3$
6. Serum Ca  $\leq 7.5$  mg/dL
7. CRP  $\geq 15$  mg/dL
8. Number of positive measures in SIRS criteria  $\geq 3$
9. Age  $\geq 70$  years

CT grade by CECT

1. Extrapaneatic progression of inflammation	
Anterior pararenal space	0 point
Root of mesocolon	1 point
Beyond lower pole of kidney	2 points
2. Hypoenhanced lesion of the pancreas	
The pancreas is conveniently divided into three segments (head, body, and tail).	
Localized in each segment or only surrounding the pancreas	0 point
Covers 2 segments	1 point
Occupies entire 2 segments or more	2 points
1 + 2 = Total score	
Total score = 0 or 1	Grade 1
Total score = 2	Grade 2
Total score = 3 or more	Grade 3

Assessment of severity

(1) If prognostic factors are scored as 3 points or more, or (2) If CT grade is judged as Grade 2 or more, the severity grading is evaluated to be as “severe”.

Measures in SIRS diagnostic criteria: (1) Temperature  $> 38$  °C or  $< 36$  °C, (2) Heart rate  $> 90$  beats/min, (3) Respiratory rate  $> 20$  breaths/min or PaCO<sub>2</sub>  $< 32$  torr, (4) WBC  $> 12,000$  cells/mm<sup>3</sup>,  $< 4,000$  cells/mm<sup>3</sup>, or  $> 10\%$  immature (band) forms

Modified from Ref. [14]


nutritional support team (NST) and other measures for severe acute pancreatitis are available.

\*The Diagnosis Procedure Combination (DPC) is a case-mix system, which is similar to the diagnosis-related groups (DRGs) used in Medicare in the United States.


#### Fluid therapy

#### *CQ12 What should be used as initial infusion solution?*


An extracellular solution (Ringer's Lactate solution, etc.) is recommended as the initial infusion solution for acute pancreatitis.



**Fig. 6** Computed tomography (CT) Grade 1 (JSS). In the contrast-enhanced CT, the mild enlargement of the entire pancreas can be observed with no noticeable poorly contrasted areas. Since fluid collection (\*) can be observed in the left anterior pararenal space and the root of the transverse mesocolon, this can be diagnosed as CT Grade 1 acute pancreatitis



**Fig. 7** Computed tomography (CT) Grade 2 (JSS). In the contrast-enhanced CT, poorly contrasted fat necrosis can be observed in the lesser sac, left anterior pararenal space and transverse mesocolon. This was diagnosed as CT Grade 2 according to the necrosis level of the pancreas (1/3-1/2) and due to the fat necrosis observed in the root of the transverse mesocolon



**Fig. 8** Computed tomography (CT) Grade 3 (JSS). In the contrast-enhanced CT, a large amount of ascites (AS) was observed. The enlargement of the pancreatic body and a poorly contrasted area (indicated by the arrows) were observed. Significant fat necrosis (\*) reaching the transverse mesocolon and left posterior peritoneal cavity space was observed. This was diagnosed as CT Grade 3 severe acute pancreatitis

#### (1C)

<Comment> According to two RCTs, Ringer's Lactate solution was found to be more effective in reducing inflammation than saline. At the same time, colloid solution HES was found to have the same reductive effect on inflammation as Ringer's Lactate solution, with a mild increase in abdominal muscle pressure [105, 106]. In an observational study of patients with severe acute pancreatitis admitted to an ICU, the volume of extracellular solution infused into survivors within 48h of admission was reported to be significantly higher than that for non-survivors [107]. Also, in a prospective study of patients with severe acute pancreatitis who exhibited shock and oliguria at the time of admission, significantly higher values for the rates of mechanical ventilation and incidences of ACS and lethal rates were obtained in the rapid fluid expansion group [108]. Although there is not sufficient reliable evidence regarding what should be used as the initial infusion solution for acute pancreatitis [109, 110], the benefits to patients when using an extracellular solution, especially Ringer's lactate solution, are considered to sufficiently outweigh the risks.

#### *CQ13 What is the optimal initial infusion rate at the onset of acute pancreatitis?*

For patients in shock or with dehydration in the early phases of acute pancreatitis, short-time rapid fluid resuscitation (150–600 mL/h: depending on the presence of shock and the dehydration level) is recommended. However, this should be carried out with great care in order to avoid excessive fluid infusion. For patients without dehydration, they

should be monitored closely with an appropriate amount of fluid infusion (130–150 mL/h). Particularly for patients with comorbidities such as cardiac or renal failure, the circulating blood volume should be carefully evaluated to determine the rate of fluid infusion.

**(1C)**

<Comment> The results of the studies regarding the initial fluid infusion rate vary according to dehydration levels. Patients with unstable circulation dynamics should be recognized as being in a severe condition with a high mortality rate, and their circulation dynamics should be more carefully evaluated and monitored. For such patients, the introduction of colloid solution infusion, catecholamine administration, and in some cases, blood purification therapy may be considered [21, 49–51, 105, 108, 109, 111–116].

*CQ14 What are the indications for the termination of initial rapid fluid infusion for acute pancreatitis?*

If a mean arterial pressure of 65 mmHg or more and a urine output of 0.5 mL/kg per hour or more has been secured in patients with acute pancreatitis, rapid fluid infusion should be discontinued and a reduction of the rate of fluid infusion is suggested. The volume of infusion should be adjusted to maintain these levels.

**(2C)**

<Comment> There are few reports on the usefulness of indicators for the termination of rapid fluid infusion. Decreases in BUN, hematocrit (Ht), and CVP have been studied, but these did not serve as useful indicators [105, 107, 110, 117]. In the Pancreatitis Bundles, one item states, “For acute pancreatitis, a sufficient amount of fluid replacement and monitoring should be performed within 48 h of onset, and mean arterial pressure (MAP) should be maintained at 65 mmHg or more and urinary output at 0.5 ml/kg per hour or more, respectively [20].” The results of a nationwide survey of patients who developed acute pancreatitis throughout the year of 2011 in Japan showed a significantly low mortality rate of 9.5% in patients in compliance with these levels, while the mortality rate of those in non-compliance was 19.4%. This showed that compliance with the Bundles can improve the life prognosis of patients [118].

Nasogastric tube

*CQ15 Is a nasogastric tube useful for the remedy of acute pancreatitis?*

No remedial effect of nasogastric tube insertion has been observed for mild acute pancreatitis. Therefore, the routine use of nasogastric suction tubes is not required.

**(1A)**

<Comment> At least eight RCTs [119–126] have been performed on nasogastric suction tube for mild to moderate pancreatitis. However, no beneficial effects such as reduced pain or shortened periods of hospitalization were reported. Rather, the duration of abdominal pain and nausea was prolonged with use of nasogastric tube [122, 125].

Pain control

*CQ16 Is pain relief necessary for acute pancreatitis?*

Pain associated with acute pancreatitis is severe and persistent, raising the need of sufficient pain control.

**(1A)**

<Comment> The appropriate use of analgesics was found to be effective in reducing pain. It was further found that this does not inhibit diagnosis or treatment [127]. A consensus has not yet been reached as to which analgesics are useful in reducing pain from acute pancreatitis [128–131].

Antibiotics prophylaxis

*CQ17 Is the prophylactic administration of antibiotics effective in improving acute pancreatitis?*

The prophylactic administration of antibiotics is not necessary in mild acute pancreatitis, since the incidence and mortality rates of infectious complications from mild acute pancreatitis are low.

**(1A)**

The prophylactic administration of antibiotics in severe acute pancreatitis and necrotizing pancreatitis may improve the prognosis, if carried out in the early phases of pancreatitis (within 72 h of onset).

**(2B)**

<Comment> Although a number of meta-analyses have been performed on the prophylactic administration of antibiotics used for acute pancreatitis, the results have not been consistent [132–160]. Many recent reports have shown that it is ineffective. However, the Meta-Analysis team for JPN Guidelines focused on the timing for starting antibiotic administration and the patients who received such treatments, and performed a meta-analysis [44] using six RCTs conducted on patients with severe acute pancreatitis or necrotizing pancreatitis within 48 and 72 h of onset [132, 133, 136, 137, 139, 141]. As a result, mortality and infectious pancreatic complication rates were significantly reduced. However, to meet the conditions of the timing to start antibiotic

administration, the type of antibiotics and the selection of subjects, a large scale RCT is considered necessary [49]. Although no clear understanding has been obtained regarding the period of prophylactic antibiotic administration, continuous administration for more than 2 weeks should be avoided in patients with no signs of infection [161]. A possible increase in complications such as fungal infections due to the use of broad-spectrum antibiotics has also been reported [162].

*CQ18 Is the prophylactic administration of antifungal agents effective for acute pancreatitis?*

No remedial effect of the prophylactic administration of antifungal agents for acute pancreatitis has been observed. Therefore, routine administration is not recommended.

**(1C)**

<Comment> Recently, no large scale RCTs have been performed on the preventive effects of antifungal administration for acute pancreatitis, and it is uncertain if such administration can reduce mortality rates or shorten the period of hospitalization [163–168].

Protease inhibitor

*CQ19 Is the intravenous administration of protease inhibitor effective for acute pancreatitis?*

The effectiveness of intravenous administration of protease inhibitor (gabexate mesilate) for improving the life prognosis and the rate of complications of acute pancreatitis has not been clearly proven. Further consideration of the efficacy of continuous high-dose intravenous administration for severe cases is required.

**(ungraded B)**

<Comment> In 17 reports [89, 169–185] on the meta-analysis of RCTs [186] published in 2014 no significant reduction in mortality rates was achieved by the administration of protease inhibitor.

Nutritional support

*CQ20 Is intravenous hyperalimentation useful for acute pancreatitis?*

Intravenous hyperalimentation is not recommended for mild cases.

**(1B)**

Total parenteral nutrition (not performed with oral or enteral nutrition) should be avoided if possible.

**(1B)**

<Comment> In two RCTs, no efficacy was observed from intravenous high calorie infusion for mild acute pancreatitis [187, 188]. In RCT conducted for severe acute pancreatitis, the medical cost of enteral nutrition for each patient was shown to be one-third of that for intravenous alimentation [189]. Also, the SIRS positive rate, CRP value and APACHE II scores were significantly lower in patients receiving enteral nutrition 7 days after admission. However, it has been also reported that these indicators did not decrease in patients receiving intravenous alimentation [190]. Furthermore, a significant decrease, not only in the rate of incidence of infectious necrotizing pancreatitis, but also in the infection rate of multiple organ failure and mortality rates were reported with enteral nutrition for severe acute pancreatitis, when compared with total parenteral nutrition [191].

*CQ21 What are the significance and indications of enteral nutrition?*

In severe cases, it is more significant as a measure to prevent infection rather than as a route of nutrition support. It can be applied and implemented for severe cases which do not have accompanying intestinal complications.

**(1A)**

<Comment> A number of RCTs have been performed in the past, in which comparisons were made between enteral nutrition and intravenous alimentation as treatments for acute pancreatitis [188–196]. A systematic review [197, 198] of these tests reported that enteral nutrition was associated with a significantly lower incidence of infection, reduced surgical intervention and a reduced length of hospital stay in comparison with total parenteral nutrition (without enteral nutrition) [197]. Therefore, enteral nutrition for severe cases is significant as an infection prevention measure, and is considered to contribute to the improvement of life prognosis.

*CQ22 When is the optimal timing to start enteral nutrition?*

If initiated in the early phase, enteral nutrition can reduce the incidence of complications and can contribute to an increased rate of survival. Therefore, it is desirable that it be started within at least 48 h of admission.

**(2A)**

<Comment> The efficacy of enteral nutrition, and a decrease in mortality rates have been demonstrated [191, 199]. Enteral nutrition can be started in the early phases of severe pancreatitis, with great care for severe ileus, intestinal ischemia and intestinal necrosis. For severe pancreatitis, enteral nutrition should be started early and at a low dose. If possible, it should begin within 48 h of admission.

*CQ23 Which administration method should be used for enteral nutrition?*

In principle, it is recommended that enteral feeding tubes be inserted into the jejunum through the Treitz ligament. However, if a feeding tube cannot be inserted into the jejunum, nutrients can be infused into the duodenum or stomach instead.

**(2B)**

<Comment> The low executing rate of early enteral nutrition has been a major issue [200]. The difficulty of inserting alimentation tubes into the jejunum may be one cause. It has been reported that enteral nutrition with gastric tube is not inferior to that with jejunal nutrition in terms of safety and complications [201–203]. Therefore, intragastric alimentation can be also used as an alternative means of administration.

*23–1: What should be used to provide enteral nutrition?*

Enteral nutrition can be provided from among digestible nutrients, semi-digestible nutrients and component nutrients, considering the viscosity and osmotic pressure.

**(B)**

<Comment> No characteristic trend has been found in analysis of the efficacy of the components of enteral nutrition, and there is not believed to be any significant difference between components [204–210].

*CQ24 When should oral administration be started?*

The initiation of oral administration should be determined using indicators such as the subsidence of abdominal pain and the serum pancreatic enzyme (especially serum lipase) level, etc.

**(2B)**

<Comment> Although abdominal pain after oral administration has not been studied in detail, D in Balthazar's CT score, duration of sustained pain, high serum lipase concentration [211] and high CRP value, high serum amylase concentration, and high serum lipase concentration in mild pancreatitis [212] are reported to be associated with the relapse of abdominal pains. The use of serum pancreatic enzymes (especially serum lipase) as an indicator to determine the timing of the start of oral administration after acute pancreatitis is considered appropriate. In mild pancreatitis, results have been reported, which support active early oral administration [213, 214].

A flowchart for the management of acute pancreatitis is shown in Figure 9.

Intensive care

*CQ25 Can peritoneal lavage (PL) for acute pancreatitis improve prognosis?*

No life-saving effect has been observed from peritoneal lavage for acute pancreatitis, and therefore it is not recommended.

**(2B)**

<Comment> Twelve RCTs [215–226] and one meta-analysis [227] of peritoneal lavage have been performed, but the diagnostic methods, severity assessment and treatment methods for acute pancreatitis are inconsistent, resulting in differing evaluations.

In both existing meta-analysis [228] and the new meta-analysis performed by the Meta-Analysis team for JPN Guidelines 2015, no effect was observed in the survival rate, incidence of complications or length of hospital stay, and therefore it was concluded that PL is not recommended.

*CQ26 When and for what types of pancreatitis should CHF/CHDF be introduced?*

For severe cases where circulation dynamics are not stable with anuria even after sufficient initial fluid infusion or cases with abdominal compartment syndrome (ACS), continuous hemofiltration (CHF)/CHDF should be introduced.

**(1C)**

The efficacy of CHF/CHDF in cases of severe acute pancreatitis not mentioned above is uncertain. Therefore, routine use is not recommended.

**(2C)**

<Comment> In a report by Pupelis et al., it was concluded that the early application of continuous venovenous hemofiltration (CVVH) facilitates the reduction of intra-abdominal hypertension (IAH) [229]. Xu et al. also reported that as a result of CVVH carried out for cases of severe acute pancreatitis with complications ACS, intra-abdominal pressure (IAP) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) were significantly decreased 24 h after CVVH commenced [230].


*CQ27 Is the continuous regional arterial infusion of protease inhibitors and antibiotics effective for acute necrotizing pancreatitis?*

Continuous regional arterial infusion therapy is reported to be effective in reducing pancreatic infection and mortality rates for severe acute pancreatitis and acute necrotizing pancreatitis, but its efficacy has not been confirmed.

**(ungraded B)**

<Comment> A number of observational studies have concluded that the continuous regional arterial infusion of

**Fig. 9** Flowchart for the management of acute pancreatitis. *ACS* abdominal compartment syndrome, *ANC* acute necrotic collection, *APFC* acute peripancreatic fluid collection, *CHF/CHDF* continuous hemo (dia)filtration, *PPC* pancreatic pseudocyst, *WON* walled-off necrosis



protease inhibitors and antibiotics is effective [231–235]. In one RCT, additional antibiotics, urgent surgical frequencies and mortality rates were significantly lower in a group treated with regional pancreatic-arterial infusion than in a group not treated with such a method [236]. However, it was pointed out that bias could not be ruled out in the case of this RCT [237]. The results of propensity score matching analysis using the Diagnosis Procedure Combination (DPC) database showed no significant differences between these two groups regarding the hospital mortality rate and infection rate of complications [238].

#### Management of biliary pancreatitis

*CQ28* For what types of gallstone-induced acute pancreatitis can early ERCP/ES be carried out?

Early ERCP/ES should be performed in gallstone-induced acute pancreatitis when complications of cholangitis or prolonged passage disorder of the biliary tract are suspected.

(1A)

<Comment> Four RCTs [239–242] were performed on early endoscopic retrograde cholangiopancreatography

(ERCP) with and without endoscopic sphincterotomy (ES) for acute pancreatitis. A meta-analysis [243] conducted for these tests concluded that both the incidence rate of complications and the mortality rate were low in the group treated with ERCP/ES. At present, early ERCP/ES should be performed for acute pancreatitis, which is diagnosed or suspected as gallstone-induced pancreatitis, in cases of: (1) complications of cholangitis; or (2) suspected prolonged passage disorder such as in the development and/or deterioration of jaundice (Fig. 10).

**CQ29** Is cholecystectomy recommended to prevent the recurrence of gallstone-induced acute pancreatitis?

To prevent the recurrence of gallstone-induced acute pancreatitis, cholecystectomy is recommended for cases where such surgery is possible.

**(1B)**

<Comment> Cholecystectomy is considered a first choice treatment for preventing the recurrence of gallstone-induced acute pancreatitis. ES+cholecystectomy is very likely to be the most effective method of preventing the recurrence of pancreatitis and biliary tract complications. The rate

of recurrence of biliary tract complications was high in the group treated solely with ERCP+ES, and where there is no reason not to perform a cholecystectomy, ERCP+ES should not be considered on its own. The rate of recurrence of pancreatitis was high in the group with no treatment, and some types of radical treatment were required [244–258].

**CQ30** What is the appropriate timing to perform cholecystectomy for gallstone-induced pancreatitis?

A cholecystectomy should be performed as soon as the gallstone-induced acute pancreatitis has been resolved.

**(1B)**

<Comment> The rate of recurrence of pancreatitis during the recovery period after discharge is reported to be 32–61%. This rate is said to be particularly high within 6 weeks after discharge [259–261]. In a systematic review of the timing of cholecystectomy for mild biliary pancreatitis, it was reported that there was no readmission when cholecystectomy was performed on patients at the time of first admission [262]. A meta-analysis on the safety of cholecystectomy within 48 h of admission has also been conducted [263].

Management of abdominal compartment syndrome


**CQ31** For what types of acute pancreatitis patients is IAP measurement necessary?

The sequential measurement of IAP is recommended for cases with excessive fluid infusion, high severity, renal and respiratory complications, and fluid accumulation in multiple areas as observed by CT, since the onset of ACS increases the mortality rate in such cases.

The measurement of IAP repeated over time is recommended for cases with excessive fluid infusion, high severity, complications of renal and respiratory disorders, and fluid accumulation in multiple areas as observed by CT, given that the onset of ACS increases the mortality rate of such cases.

**(2C)**

<Comment> In acute pancreatitis, complications can be induced by increased IAP. The World Society of Abdominal Compartment Syndrome (WSACS) defines this as where intra-abdominal hypertension (IAH) persists at levels of  $IAP \geq 12$  mmHg [264, 265]. Moreover, IAH with a series of pathological conditions including organ failure caused by ischemia in intra-abdominal and retroperitoneal organs, and circulatory failure associated with respiratory failure and anomalous venous return caused by diaphragmatic eventration and increased intrathoracic pressure and is referred to as ACS. ACS is defined as cases with



**Fig. 10** Flowchart for the management of biliary pancreatitis. ERCP/ES endoscopic retrograde cholangiopancreatography with or without endoscopic sphincterotomy

IAP > 20 mmHg accompanied by new organ disorder/failure [264, 265].

The mortality rate of acute pancreatitis with complication of ACS varies depending on the report [266–275], but a systematic review by van Brunschot et al. showed a high mortality rate of 47.5% [276]. Also, a large number of complications from organ disorder/failure have been shown. The mortality rate of regional pancreatic infection complicated with ACS is reported to be 24.0–66.7% [267, 268, 272, 275, 276]. Acute pancreatitis with excessive fluid infusion, high severity, renal disorders, creatinine levels, complications of respiratory disorders, tachypnea, and fluid collection in multiple areas, as observed by CT, is likely to develop IAH/ACS [108, 266, 277, 278], and the measurement of IAP over time is necessary.

#### *CQ32 How should IAH/ACS be treated?*

When there is persistent or recurrent IAP  $\geq$  12 mmHg, conservative treatment (gastrointestinal decompression, intra-abdominal decompression, improvement of abdominal wall compliance, appropriate fluid infusion and circulation management) should be initiated. The goal should be to manage for IAP  $\leq$  15 mmHg. Surgical decompression should be considered only when internal treatment is not effective for patients with IAP > 20 mmHg and where the additional complication of organ failure is of concern.

#### **(2D)**

<Comment> In 2013, WSASC recommended that conservative treatment for IAH be carried out first [279]. The proposed procedure for treatment is the step-wise implementation of gastrointestinal decompression, intra-abdominal decompression, improvement of abdominal wall compliance, and appropriate fluid infusion and circulation management for the entire body and local areas. Also, the implementation of surgical decompression is suggested when internal treatment is not effective for patients with IAP > 20 mmHg and when new organ disorders appear. Chen et al. reported a success rate of medical treatment of 75.0% [268]. Also, Boone et al. reported the performance of surgical depression for all cases with ACS complications [280].

#### Interventions for local complications

#### *CQ33 What are the indications for therapeutic intervention in local pancreatic complications?*

In principle, conservative treatments should first be performed for necrotizing pancreatitis. The best indication for intervention is applied to cases of infected necrotizing pancreatitis with suspected or confirmed infection accompanying an aggravated general condition.

#### **(1C)**

<Comment> Given that the mortality rate from early operations (within 72 h of onset) is very high [281], conservative treatment should be first performed for necrotizing pancreatitis. High mortality rates of 12–26% are observed for ANC or WON accompanying infections [282–284], and intervention treatment is recommended for infectious necrotizing pancreatitis with suspected or confirmed infection accompanying an aggravated general condition [47, 285, 286]. However, conservative treatments such as antibiotic administration can be prioritized for stable general conditions, even if a diagnosis of infectious necrotizing pancreatitis has been made [284, 287]. Rare indications include closed gastric drainage due to PPC [288–291], or a restricted or closed pancreatic duct or intrapancreatic bile duct due to necrosis of pancreatic parenchyma, etc. [292, 293].

#### *CQ34 How should infected pancreatic necrosis be diagnosed?*

Infected pancreatic necrosis should be suspected when clinical symptoms and blood test findings deteriorate. Routine use of fine needle-aspiration (FNA) is not required for diagnosis, and clinical signs and CT should be used for a comprehensive determination. If an aggravated general condition is observed, percutaneous drainage or endoscopic drainage should be given for diagnosis and treatment.

#### **(1C)**

<Comment> Findings suggestive of infected pancreatic necrosis are a deterioration of clinical symptoms and blood test results, a positive bacterial blood culture test, a positive endotoxin test and increased procalcitonin values [294, 295], as well as CT-identified gas in the pancreas or peripancreatic tissues. As direct diagnostic methods for infectious necrotizing pancreatitis, CT or US guided FNA can be used for bacteriological examination [296, 297]. In the past, the routine use of FNA was recommended when infectious necrotizing pancreatitis was suspected, but this indication has become more limited recently [282, 298–300].

#### *CQ35 When should therapeutic intervention for infected pancreatic necrosis be carried out?*

If possible, therapeutic intervention for infected pancreatic necrosis should be performed after 4 weeks of onset, when the necrosis has been sufficiently walled off, or in other words, during the WON period.

#### **(2C)**

<Comment> The mortality rate of necrotizing pancreatitis is significantly high from necrosectomy in the early phases [281, 301, 302] and thus it is recommended to perform necrosectomy after at least 4 weeks after the onset of acute pancreatitis when necrosis has been sufficiently walled off

[47, 287, 303]. When infectious necrotizing pancreatitis is suspected, postponing intervention treatment is recommended until 4 weeks after onset when ANC becomes WON.

*CQ36 How should the therapeutic intervention for infected pancreatic be selected?*

During therapeutic intervention for infected pancreatic necrosis, percutaneous (retroperitoneal) drainage or endoscopic transluminal drainage should be first given, and if no improvement is achieved, necrosectomy should then be performed. Necrosectomy by endoscopic or retroperitoneal approach is recommended.

**(2B)**

<Comment> As intervention treatment for infectious necrotizing pancreatitis, a step-wise approach has been proposed [304], and the selection of minimally invasive method such as percutaneous (retroperitoneal) drainage or endoscopic transluminal drainage has been recommended [47, 287, 304–307]. Necrosectomy should be considered necessary in cases where drainage is not effective. Regarding the methods of necrosectomy, the efficacy of video-assisted retroperitoneal debridement (VARD) and endoscopic necrosectomy has been shown [284, 305, 308]. Regarding approach methods, the retroperitoneal approach has fewer complications than the laparotomy approach [309, 310].

Post-ERCP pancreatitis

*CQ37 Which endoscopic procedure is effective for the prevention of post-ERCP pancreatitis?*

Prophylactic temporary pancreatic stent placement is useful as an effective endoscopic procedure for the prevention of post-ERCP pancreatitis. This should only be performed in the high-risk groups\* for post-ERCP pancreatitis given the risks and cost.

**(2A)**

The guidewire method is very likely to reduce the incidence of post-ERCP pancreatitis.

**(2A)**

<Comment> A number of RCTs and meta-analyses have been performed on prophylactic temporary pancreatic stent placement for high-risk groups of post-ERCP pancreatitis. In most studies stent placement is reported to be effective for the prevention of pancreatitis [311–329]. Meta-analysis was conducted on cannulation methods using contrast agent infusion and guidewires. As a result, a significant reduction of post-ERCP pancreatitis was observed in the group treated with the guidewire method. Therefore, the guidewire method can be used as a first choice therapy [330].

\*The high-risk group for post-ERCP pancreatitis refers to patients with confirmed or suspected Sphincter of Oddi dysfunction, patients for whom cannulation is difficult, patients for whom pre-cut sphincterotomy has been performed, or patients for whom balloon dilatation has been provided.

*CQ38 Which drug therapy is effective for the prevention of post-ERCP pancreatitis? What are the indications for this?*

For the prevention of post-ERCP pancreatitis, the intrarectal administration of NSAIDs should be carried out for all cases undergoing ERCP with no contraindications.

**(2A)**

Other drugs should not be used as routine preventive measures, since their efficacy has been refuted or is uncertain.

<Comment> NSAIDs administration significantly inhibited the onset of post-ERCP pancreatitis [331–334]. Regarding modes of administration, intrarectal administration significantly inhibited the onset of post-ERCP pancreatitis [335, 336].

Clinical indicators

*CQ39 Can compliance with the guidelines and bundles improve patient prognosis?*

A high rate of implementation of the pancreatitis bundles may contribute to improving prognosis of patients with severe acute pancreatitis.

**(1C)**

<Comment> Patients who received treatment, report greater satisfaction in more than eight items of the Pancreatitis Bundles (2010) and showed significantly lower mortality rates than patients who received treatments that satisfied seven items or less [118].

In a questionnaire conducted in Germany, it was reported that although surgeons in Germany were aware of the guidelines for the management of acute pancreatitis, approximately 50% performed treatments that varied from the guidelines [337]. It has been reported, however, that since the publication of the French guidelines, treatments that are more in line with the guidelines have been carried out in France [338]. It is also reported that in Britain, the introduction of Pathway improved the performance rates of CT, severity assessments and ICU admission [339]. From the above reports, compliance with the guidelines and Bundles may lead to the improvement of prognosis, but further consideration is still required (Table 5).

**Table 5** Pancreatitis Bundles 2015

In principle, compliance with all of the items is recommended for acute pancreatitis, except under special circumstances. Whether or not compliance with the items has been carried out should be detailed on the medical record.

1. When a diagnosis of acute pancreatitis is made, repeated severity assessments should be carried out at diagnosis, and within 24 h, and 24–48 h after diagnosis based on the JPN Severity Score (JSS).
2. For patients with severe acute pancreatitis, transfer to an appropriate medical facility should be considered within 3 h after diagnosis has been made.
3. For patients with acute pancreatitis, causes of pancreatitis should be differentiated within 3 h after diagnosis, using medical records, hematological examination and imaging studies.
4. For gallstone-induced pancreatitis, early ERC + ES should be considered in patients with accompanying cholangitis and/or prolonged passage disorder of the biliary tract including the occurrence or aggravation of jaundice.
5. At a medical facility where treatment for severe acute pancreatitis is performed, abdominal contrast-enhanced CT studies should be performed within 3 h after initial treatment. A non-enhanced area and the extent of the disease should be examined, and severity should be assessed on the basis of the CT grades of acute pancreatitis.
6. For acute pancreatitis, sufficient amounts of fluid replacement and monitoring should be performed within 48 h of onset, and mean arterial pressure (MAP): diastolic blood pressure + (systolic blood pressure - diastolic blood pressure)/3 should be maintained at 65 mmHg or more and urinary output at 0.5 ml/kg per h or more, respectively.
7. Pain control should be provided for acute pancreatitis.
8. Prophylactic wide-spectrum antibiotics should be administered for severe acute pancreatitis within 72 h of onset.
9. Even if intestinal peristalsis is not present, enteral nutrition should be started in small amounts (jejunal administration is desirable) within 48 h of diagnosis.
10. Cholecystectomy should be performed after the subsiding of symptoms of pancreatitis for gallstone-induced pancreatitis accompanied by cholelithiasis.

## Conclusion

The latest evidence-based guidelines for the management of acute pancreatitis have been prepared with a clearly described scope and purpose using the GRADE system. For subject areas where no results have been obtained, new meta-analysis was conducted for the grading of recommendations. Also, the Pancreatitis Bundles 2015 was established, which can enhance awareness for improvements in the quality of treatment. Furthermore, the JPN Guidelines 2015 provide a mobile application that can be used easily in a daily clinical situation. Effort has been made to maintain transparency and neutrality during the preparation of these guidelines. The most up-to-date preparation methods and recommendations were used. In this way, we are confident that clinicians will be able to easily follow these guidelines and that these guidelines will contribute to improve the treatment of acute pancreatitis. Above all, it is hoped that the JPN Guidelines 2015 will be used to determine treatments for patients and will contribute to optimal support for them.

**Acknowledgments** The authors thank Machiko Inoue, Tomohiko Ukai, Yoshinori Noguchi of the Meta-Analysis team for JPN Guidelines 2015. All expenses incurred in the preparation and publication of these guidelines were paid by the relevant academic societies and research teams.

**Conflict of interest** Y. Takeyama has received honoraria from Ajinomoto Pharmaceuticals Co., Ltd., Tokyo, Japan.

Prior to the preparation of these medical guidelines, all members of the Guidelines Revision Committee declared any conflicts of interest

(COI). Effort was made to avoid biases in the guidelines with regard to economic issues. Effort was also made to create a cooperative system with a number of relevant academic societies and research organizations, in order to avoid academic conflicts of interest among individual academic societies.

## Appendix: author's affiliations

Masamichi Yokoe, General Internal Medicine, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan; Tadahiro Takada and Keita Wada, Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan; Toshihiko Mayumi, Department of Emergency Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; Masahiro Yoshida, Department of Hemodialysis and Surgery, Chemotherapy Research Institute, International University of Health and Welfare, Ichikawa, Japan; Shuji Isaji, Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Mie, Japan; Takao Itoi, Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan; Naohiro Sata, Department of Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan; Toshifumi Gabata, Department of Radiology, Kanazawa University, School of Medical Science, Kanazawa, Japan; Hisato Igarashi, Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan; Keisho Kataoka, Otsu Municipal Hospital Shiga and Kyoto Prefectural University of Medicine, Kyoto, Japan; Masahiko Hirota, Department of Surgery, Kumamoto Regional Medical Center, Kumamoto, Japan; Masumi Kadoya, Department of Radiology, Shinshu University School of

Medicine, Matsumoto, Japan; Nobuya Kitamura, Department of Emergency and Critical Care Medicine, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan; Yasutoshi Kimura and Koichi Hirata, Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan; Seiki Kiriyama, Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan; Kunihiro Shirai, Department of Emergency and Critical Care Medicine, Ichinomiya Municipal Hospital, Ichinomiya, Japan; Takayuki Hattori, Department of Radiology, Tokyo Metropolitan Health and Medical Treatment Corporation, Ohkubo Hospital, Tokyo, Japan; Kazunori Takeda, Department of Surgery, National Hospital Organization Sendai Medical Center, Sendai, Japan; Yoshifumi Takeyama, Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan; Morihisa Hirota, Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan; Miho Sekimoto, The University of Tokyo Graduate School of Public Policy, Health Policy Unit, Tokyo, Japan; Satoru Shikata, Department of Family Medicine, Mie Prefectural Ichishi Hospital, Mie, Japan; Shinju Arata, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.

The QR codes (for iPhone and Android) to download the mobile application can be found at <http://www.jshbps.jp/en/guideline/jpn-guideline2015.html>.

## References

1. Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, et al. JPN Guidelines for the management of acute pancreatitis: cutting-edge information. *J Hepatobiliary Pancreat Surg.* 2006;13:2–6.
2. Yoshida M, Takada T, Kawarada Y, Hirata K, Mayumi T, Sekimoto M, et al. Health insurance system and payments provided to patients for the management of severe acute pancreatitis in Japan. *J Hepatobiliary Pancreat Surg.* 2006;13:7–9.
3. Sekimoto M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. *J Hepatobiliary Pancreat Surg.* 2006;13:10–24.
4. Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: diagnostic criteria for acute pancreatitis. *J Hepatobiliary Pancreat Surg.* 2006;13:25–32.
5. Hirota M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: severity assessment of acute pancreatitis. *J Hepatobiliary Pancreat Surg.* 2006;13:33–41.
6. Takeda K, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: medical management of acute pancreatitis. *J Hepatobiliary Pancreat Surg.* 2006;13:42–7.
7. Isaji S, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: surgical management. *J Hepatobiliary Pancreat Surg.* 2006;13:48–55.
8. Kimura Y, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: treatment of gallstone-induced acute pancreatitis. *J Hepatobiliary Pancreat Surg.* 2006;13:56–60.
9. Mayumi T, Takada T, Kawarada Y, Hirata K, Yoshida M, Sekimoto M, et al. Management strategy for acute pancreatitis in the JPN Guidelines. *J Hepatobiliary Pancreat Surg.* 2006;13:61–7.
10. Takada T, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, et al. Cutting-edge information for the management of acute pancreatitis. *J Hepatobiliary Pancreat Sci.* 2010;17:3–12.
11. Yoshida M, Takada T, Hirata K, Mayumi T, Shikata S, Shirai K, et al. Health insurance and payment systems for severe acute pancreatitis. *J Hepatobiliary Pancreat Sci.* 2010;17:13–6.
12. Sekimoto M, Shikata S, Takada T, Hirata K, Yoshida M, Hirota M, et al. Changes in management of acute pancreatitis before and after the publication of evidence-based practice guidelines in 2003. *J Hepatobiliary Pancreat Sci.* 2010;17:17–23.
13. Kiriyama S, Gabata T, Takada T, Hirata K, Yoshida M, Mayumi T, et al. New diagnostic criteria of acute pancreatitis. *J Hepatobiliary Pancreat Sci.* 2010;17:24–36.
14. Takeda K, Yokoe M, Takada T, Kataoka K, Yoshida M, Gabata T, et al. Assessment of severity of acute pancreatitis according to new prognostic factors and CT grading. *J Hepatobiliary Pancreat Sci.* 2010;17:37–44.
15. Hirota M, Takada T, Kitamura N, Ito T, Hirata K, Yoshida M, et al. Fundamental and intensive care of acute pancreatitis. *J Hepatobiliary Pancreat Sci.* 2010;17:45–52.
16. Amano H, Takada T, Isaji S, Takeyama Y, Hirata K, Yoshida M, et al. Therapeutic intervention and surgery of acute pancreatitis. *J Hepatobiliary Pancreat Sci.* 2010;17:53–9.
17. Kimura Y, Arata S, Takada T, Hirata K, Yoshida M, Mayumi T, et al. Gallstone-induced acute pancreatitis. *J Hepatobiliary Pancreat Sci.* 2010;17:60–9.
18. Arata S, Takada T, Hirata K, Yoshida M, Mayumi T, Hirota M, et al. Post-ERCP pancreatitis. *J Hepatobiliary Pancreat Sci.* 2010;17:70–8.
19. Wada K, Takada T, Hirata K, Mayumi T, Yoshida M, Yokoe M, et al. Treatment strategy for acute pancreatitis. *J Hepatobiliary Pancreat Sci.* 2010;17:79–86.
20. Mayumi T, Takada T, Hirata K, Yoshida M, Sekimoto M, Hirota M, et al. Pancreatitis bundles. *J Hepatobiliary Pancreat Sci.* 2010;17:87–9.
21. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. *Gut.* 2013;62:102–11.
22. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE working group. Grading quality of evidence and strength of recommendations. *BMJ.* 2004;328:1490.
23. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008;336:924–6.
24. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, et al. GRADE Working Group. What is "quality of evidence" and why is it important to clinicians? *BMJ.* 2008;336:995–8.
25. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ.* 2008;336:1106–10.
26. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, et al. GRADE working group. Incorporating considerations of resources use into grading recommendations. *BMJ.* 2008;336:1170–3.

27. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. GRADE Working Group. Going from evidence to recommendations. *BMJ*. 2008;336:1049–51.
28. Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, et al. GRADE working group. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. *BMJ*. 2008;337:a744.
29. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64:383–94.
30. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol*. 2011;64:395–400.
31. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol*. 2011;64:401–6.
32. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). *J Clin Epidemiol*. 2011;64:407–15.
33. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence—publication bias. *J Clin Epidemiol*. 2011;64:1277–82.
34. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. *J Clin Epidemiol*. 2011;64:1283–93.
35. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. *J Clin Epidemiol*. 2011;64:1294–302.
36. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence—indirectness. *J Clin Epidemiol*. 2011;64:1303–10.
37. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol*. 2011;64:1311–6.
38. Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. *J Clin Epidemiol*. 2013;66:140–50.
39. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *J Clin Epidemiol*. 2013;66:151–7.
40. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables—binary outcomes. *J Clin Epidemiol*. 2013;66:158–72.
41. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles—continuous outcomes. *J Clin Epidemiol*. 2013;66:173–83.
42. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol*. 2013;66:719–25.
43. Andrews J, Guyatt G, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendations—determinants of a recommendation’s direction and strength. *J Clin Epidemiol*. 2013;66:726–35.
44. Ukai T, Shikata S, Inoue M, Noguchi Y, Igarashi H, Isaji S, et al. Early prophylactic antibiotics administration for acute necrotizing pancreatitis: a meta-analysis of randomized controlled trials. *J Hepatobiliary Pancreat Sci*. 2015;22:316–21.
45. UK Working Party on Acute Pancreatitis. Working Party of the British Society of Gastroenterology; Association of Surgeons of Great Britain and Ireland; Pancreatic Society of Great Britain and Ireland; Association of Upper GI Surgeons of Great Britain and Ireland. UK Guidelines for the Management of Acute Pancreatitis. *Gut*. 2005; 54:iii1–9.
46. Sargent S. Pathophysiology, diagnosis and management of acute pancreatitis. *Br J Nurs*. 2006; 15:999–1005.
47. Banks PA, Freeman ML. Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. *Am J Gastroenterol*. 2006;101:2379–400.
48. Pezzilli R, Zerbi A, Di Carlo V, Bassi C, Delle Fave GF. Working Group of the Italian Association for the Study of the Pancreas on Acute Pancreatitis. Practical guidelines for acute pancreatitis. *Pancreatol*. 2010;10:523–35.
49. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatol*. 2013;13:e1–15.
50. Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol*. 2013;108:1400–15.
51. Poma EM, Olascoaga FZ, Petrov MS, Soto SN, Santos CL, Alava FM, et al. Group-PSAP 2012. GTEL-SEMICYUC. SEMICYUC 2012. Recommendations for intensive care management of acute pancreatitis. *Med Intensiva*. 2013;37:163–79.
52. Otsuki M, Takeda K, Matsuno S, Kihara Y, Koizumi M, Hirota M, et al. Criteria for the diagnosis and severity stratification of acute pancreatitis. *World J Gastroenterol*. 2013;19:5798–805.
53. Vissers RJ, Abu-Laban RB, McHugh DF. Amylase and lipase in the emergency department evaluation of acute pancreatitis. *J Emerg Med*. 1999;17:1027–37.
54. Chang K, Lu W, Zhang K, Jia S, Li F, Wang F, et al. Rapid urinary trypsinogen-2 test in the early diagnosis of acute pancreatitis: a meta-analysis. *Clin Biochem*. 2012;45:1051–6.
55. Jin T, Huang W, Jiang K, Xiong JJ, Xue P, Javed MA, et al. Urinary trypsinogen-2 for diagnosing acute pancreatitis: a meta-analysis. *Hepatobiliary Pancreat Dis Int*. 2013;12:355–62.
56. Skipworth JR, Pereira SP. Acute pancreatitis. *Curr Opin Crit Care*. 2008;14:172–8.
57. Silverstein W, Isikoff MB, Hill MC, Barkin J. Diagnostic imaging of acute pancreatitis: prospective study using CT and sonography. *Am J Roentgenol*. 1981;137:497–502.
58. Jeffrey RB Jr, Laing FC, Wing VW. Extrapancreatic spread of acute pancreatitis: new observations with real-time US. *Radiology*. 1986;159:707–11.
59. Dorffel Y, Wruck U, Ruckert RI, Romaniuk P, Dörfel Q, Wermke W. Vascular complication in acute pancreatitis assessed by color Duplex ultrasonography. *Pancreas*. 2000;21:126–33.
60. Balthazar EJ, Freeny PC, van Sonnenberg E. Imaging and intervention in acute pancreatitis. *Radiology*. 1994;193:297–306.
61. Lin A, Feller ER. Pancreatic carcinoma as a cause of unexplained pancreatitis: report of ten cases. *Ann Intern Med*. 1990;112:166–7.
62. Mujica VR, Barkin JS, Go VL. Acute pancreatitis secondary to pancreatic carcinoma. *Pancreas*. 2000;21:329–32.
63. Shyu JY, Sainani NI, Sahni VA, Chick JF, Chauhan NR, Conwell DL, et al. Necrotizing pancreatitis: diagnosis, imaging, and intervention. *RadioGraphics*. 2014;34:1218–39.
64. Zaheer A, Singh VK, Qureshi RO, Fishman EK. The revised Atlanta classification for acute pancreatitis: updates in imaging terminology and guidelines. *Abdom Imaging*. 2013;38:125–36.
65. Thoeni RF. The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. *Radiology*. 2012;262:751–64.

66. Takahashi N, Papachristou GI, Schmit GD, Chahal P, LeRoy AJ, Sarr MG, et al. CT findings of walled-off pancreatic necrosis (WOPN): differentiation from pseudocyst and prediction of outcome after endoscopic therapy. *Eur Radiol.* 2008;18:2522–9.
67. Miller FH, Keppke AL, Dalal K, Ly JN, Kamler VA, Sica GT. MRI of pancreatitis and its complications: part 1, Acute pancreatitis. *Am J Roentgenol.* 2004;183:1637–44.
68. Morgan DE, Baron TH, Smith JK, Robbin ML, Kenney PJ. Pancreatic fluid collections prior to intervention: evaluation with MR imaging compared with CT and US. *Radiology.* 1997;203:773–8.
69. Hirota M, Kimura Y, Ishiko T, Beppu T, Yamashita Y, Ogawa M. Visualization of the heterogeneous internal structure of so-called “pancreatic necrosis” by magnetic resonance imaging in acute necrotizing pancreatitis. *Pancreas.* 2002;25:63–7.
70. Ward J, Chalmers AG, Guthrie AJ, Larvin M, Robinson PJ. T2-weighted and dynamic enhanced MRI in acute pancreatitis: comparison with contrast enhanced CT. *Clin Radiol.* 1997;52:109–14.
71. Piironen A, Kivisaari R, Kempainen E, Laippala P, Koivisto AM, Poutanen VP, et al. Detection of severe acute pancreatitis by contrast-enhanced magnetic resonance imaging. *Eur Radiol.* 2000;10:354–61.
72. Mortelet KJ, Mergo PJ, Taylor HM, Wiesner W, Cantisani V, Ernst MD, et al. Peripancreatic vascular abnormalities complicating acute pancreatitis: contrast-enhanced helical CT findings. *Eur J Radiol.* 2004;52:67–72.
73. Vujic I, Anderson BL, Stanley JH, Gobien RP. Pancreatic and peripancreatic vessels: embolization for control bleeding in pancreatitis. *Radiology.* 1984;150:51–5.
74. Waltman A, Luers P, Athanasoulis C, Warshaw AL. Massive arterial hemorrhage in patients with pancreatitis: Complementary roles of surgery and transcatheter occlusive techniques. *Arch Surg.* 1986;121:439–43.
75. Parvey HR, Raval B, Sandler CM. Portal vein thrombosis: imaging findings. *Am J Roentgenol.* 1994;162:77–81.
76. Pezzilli R, Uomo G, Zerbi A, Gabbiellini A, Frulloni L, De Rai P, et al. Diagnosis and treatment of acute pancreatitis: the position statement of the Italian Association for the study of the pancreas. *Dig Liver Dis.* 2008;40:803–8.
77. Liu CL, Fan ST, Lo CM, Tso WK, Wong Y, Poon RT, et al. Clinico-biochemical prediction of biliary cause of acute pancreatitis in the era of endoscopic ultrasonography. *Aliment Pharmacol Ther.* 2005;22:423–31.
78. Lomas DJ, Bearcroft PW, Gimson AE. MR cholangiopancreatography: prospective comparison of a breath-hold 2D projection technique with diagnostic ERCP. *Eur Radiol.* 1999;9:1411–7.
79. Hirohashi S, Hirohashi R, Uchida H, Akira M, Itoh T, Haku E, et al. Pancreatitis: evaluation with MR cholangiopancreatography in children. *Radiology.* 1997;203:411–5.
80. Liu CL, Lo CM, Chan HKF, Poon RT, Lam CM, Fan ST, et al. Detection of choledocholithiasis by EUS in acute pancreatitis: a prospective evaluation in 100 consecutive patients. *Gastrointest Endosc.* 2001;54:325–30.
81. Chak A, Hawes RH, Cooper GS, Hoffman B, Catalano MF, Wong RC, et al. Prospective assessment of the utility of EUS in the evaluation of gallstone pancreatitis. *Gastrointest Endosc.* 1999;49:599–604.
82. Liu CL, Lo CM, Chan JK, Poon RT, Fan ST. EUS for detection of occult cholelithiasis in patients with idiopathic pancreatitis. *Gastrointest Endosc.* 2000;51:28–32.
83. Norton SA, Alderson D. Endoscopic ultrasonography in the evaluation of idiopathic acute pancreatitis. *Br J Surg.* 2000;87:1650–5.
84. Frossard JL, Sosa-Valencia L, Amouyal G, Marty O, Hadengue A, Amouyal P. Usefulness of endoscopic ultrasonography in patients with “idiopathic” acute pancreatitis. *Am J Med.* 2000;109:196–200.
85. Tenner S. Initial management of acute pancreatitis: critical issues during the first 72 hours. *Am J Gastroenterol.* 2004;99:2489–94.
86. Ranson JH, Pasternack BS. Statistical methods for quantifying the severity of clinical acute pancreatitis. *J Surg Res.* 1977;22:79–91.
87. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med.* 1985;13:818–29.
88. Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC. Prognostic signs and the role of operative management in acute pancreatitis. *Surg Gynecol Obstet.* 1974;139:69–81.
89. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. *Br J Surg.* 1978;65:337–41.
90. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest.* 1992;101:1644–55.
91. Brown A, James-Stevenson T, Dyson T, Grunckenmeier D. The panc 3 score: a rapid and accurate test for predicting severity on presentation in acute pancreatitis. *J Clin Gastroenterol.* 2007;41:855–8.
92. Harrison DA, D'Amico G, Singer M. The Pancreatitis Outcome Prediction (POP) Score: a new prognostic index for patients with severe acute pancreatitis. *Crit Care Med.* 2007;35:1703–8.
93. Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. *Gut.* 2008;57:1698–703.
94. Lankisch PG, Weber-Dany B, Hebel K, Maisonneuve P, Lowenfels AB. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. *Clin Gastroenterol Hepatol.* 2009;7:702–5.
95. Yang CJ, Chen J, Phillips AR, Windsor JA, Petrov MS. Predictors of severe and critical acute pancreatitis: a systematic review. *Dig Liver Dis.* 2014;46:446–51.
96. Mounzer R, Langmead CJ, Wu BU, Evans AC, Bishehsari F, Muddana V, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. *Gastroenterology.* 2012;142:1476–82.
97. Vesentini S, Bassi C, Talamini G, Cavallini G, Campedelli A, Pederzoli P. Prospective comparison of C-reactive protein level, Ranson score and contrast-enhanced computed tomography in the prediction of septic complications of acute pancreatitis. *Br J Surg.* 1993;80:755–7.
98. Kempainen E, Sainio V, Haapiainen R, Kivisaari L, Kivilaakso E, Puolakkainen P. Early localization of necrosis by contrast-enhanced computed tomography can predict outcome in severe acute pancreatitis. *Br J Surg.* 1996;83:924–9.
99. Bradley EL 3rd, Murphy F, Ferguson C. Prediction of pancreatic necrosis by dynamic pancreatography. *Ann Surg.* 1989;210:495–503.
100. Larvin M, Chalmers AG, McMahon MJ. Dynamic contrast enhanced computed tomography: a precise technique for identifying and localizing pancreatic necrosis. *Br Med J.* 1990;300:1425–8.
101. London NJ, Leese T, Lavelle JM, Miles K, West KP, Watkin DF, et al. Rapid-bolus contrast-enhanced dynamic computed tomography in acute pancreatitis: a prospective study. *Br J Surg.* 1991;78:1452–6.
102. Singla A, Simons J, Li Y, Csikesz NG, Ng SC, Tseng JF, et al. Admission volume determines outcome for patients with acute pancreatitis. *Gastroenterology.* 2009;137:1995–2001.
103. Murata A, Matsuda S, Mayumi T, Yokoe M, Kuwabara K, Ichimiya Y, et al. Effect of hospital volume on clinical outcome

- in patients with acute pancreatitis, based on a national administrative database. *Pancreas*. 2011;40:1018–23.
104. Shen HN, Lu CL, Li CY. The effect of hospital volume on patient outcomes in severe acute pancreatitis. *BMC Gastroenterol*. 2012;12:112.
  105. Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S, et al. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. *Clin Gastroenterol Hepatol*. 2011;9:710–7.e1.
  106. Du XJ, Hu WM, Xia Q, Huang ZW, Chen GY, Jin XD, et al. Hydroxyethyl starch resuscitation reduces the risk of intra-abdominal hypertension in severe acute pancreatitis. *Pancreas*. 2011;40:1220–5.
  107. Mole DJ, Hall A, McKeown D, Garden OJ, Parks RW. Detailed fluid resuscitation profiles in patients with severe acute pancreatitis. *HPB*. 2011;13:51–8.
  108. Mao EQ, Tang YQ, Fei J, Qin S, Wu J, Li L, et al. Fluid therapy for severe acute pancreatitis in acute response stage. *Chin Med J (Engl)*. 2009;122:169–73.
  109. Haydock MD, Mittal A, Wilms HR, Phillips A, Petrov MS, Windsor JA. Fluid therapy in acute pancreatitis: anybody's guess. *Ann Surg*. 2013;257:182–8.
  110. Sarr MG. Early fluid “resuscitation/therapy” in acute pancreatitis: which fluid? What rate? What parameters to gauge effectiveness? *Ann Surg*. 2013;257:189–90.
  111. Wall I, Badalov N, Baradaran R, Iswara K, Li JJ, Tenner S. Decreased mortality in acute pancreatitis related to early aggressive hydration. *Pancreas*. 2011;40:547–50.
  112. Gardner TB, Vege SS, Chari ST, Petersen BT, Topazian MD, Clain JE, et al. Faster rate of initial fluid resuscitation in severe acute pancreatitis diminishes in-hospital mortality. *Pancreatol*. 2009;9:770–6.
  113. de-Madaria E, Soler-Sala G, Sanchez-Paya J, Lopez-Font I, Martinez J, Gomez-Escolar L, et al. Influence of fluid therapy on the prognosis of acute pancreatitis: a prospective cohort study. *Am J Gastroenterol*. 2011;106:1843–50.
  114. Eckerwall G, Olin H, Andersson B, Andersson R. Fluid resuscitation and nutritional support during severe acute pancreatitis in the past: What have we learned and how can we do better? *Clin Nutr*. 2006;25:497–504.
  115. Warndorf MG, Kurtzman JT, Bartel MJ, Cox M, Mackenzie T, Robinson S, et al. Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. *Clin Gastroenterol Hepatol*. 2011;9:705–9.
  116. Kuwabara K, Matsuda S, Fushimi K, Ishikawa KB, Horiguchi H, Fujimori K. Early crystalloid fluid volume management in acute pancreatitis: association with mortality and organ failure. *Pancreatol*. 2011;11:351–61.
  117. Mao EQ, Fei J, Peng YB, Huang J, Tang YQ, Zhang SD. Rapid hemodilution is associated with increased sepsis and mortality among patients with severe acute pancreatitis. *Chin Med J (Engl)*. 2010;123:1639–44.
  118. Hirota M, Mayumi T, Shimosegawa T. Acute pancreatitis bundles: 10 clinical regulations for the early management of patients with severe acute pancreatitis in Japan. *J Hepatobiliary Pancreat Sci*. 2014;21:829–30.
  119. Levant JA, Secrist DM, Resin H, Sturdevant RA, Guth PH. Nasogastric suction in the treatment of alcoholic pancreatitis. A controlled study. *JAMA*. 1974;229:51–2.
  120. Naeije R, Salingret E, Clumeck N, De Troyer A, Devis G. Is nasogastric suction necessary in acute pancreatitis? *Br Med J*. 1978;2:659–60.
  121. Field BE, Hepner GW, Shabot MM, Schwartz AA, State D, Worthen N, et al. Nasogastric suction in alcoholic pancreatitis. *Dig Dis Sci*. 1979;24:339–44.
  122. Fuller RK, Loveland JP, Frankel MH. An evaluation of the efficacy of nasogastric suction treatment in alcoholic pancreatitis. *Am J Gastroenterol*. 1981;75:349–53.
  123. Goff JS, Feinberg LE, Brugge WR. A randomized trial comparing cimetidine to nasogastric suction in acute pancreatitis. *Dig Dis Sci*. 1982;27:1085–8.
  124. Louidice TA, Lang J, Mehta H, Banta L. Treatment of acute alcoholic pancreatitis: the roles of cimetidine and nasogastric suction. *Am J Gastroenterol*. 1984;79:553–8.
  125. Navarro S, Ros E, Aused R, García Pugés M, Piqué JM, Vilar BJ. Comparison of fasting, nasogastric suction and cimetidine in the treatment of acute pancreatitis. *Digestion*. 1984;30:224–30.
  126. Sarr MG, Sanfey H, Cameron JL. Prospective, randomized trial of nasogastric suction in patients with acute pancreatitis. *Surgery*. 1986;100:500–4.
  127. Meng W, Yuan J, Zhang C, Bai Z, Zhou W, Yan J, et al. Parenteral analgesics for pain relief in acute pancreatitis: a systematic review. *Pancreatol*. 2013;13:201–6.
  128. Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ. Making health care safer: a critical analysis of patient safety practices. *Evid Rep Technol Assess (Summ)*. 2001;43:i–x, 1–668.
  129. Jakobs R, Adamek MU, von Bubnoff AC, Riemann JF. Buprenorphine or procaine for pain relief in acute pancreatitis. A prospective randomized study. *Scand J Gastroenterol*. 2000;35:1319–23.
  130. Kahl S, Zimmermann S, Pross M, Schulz HU, Schmidt U, Malfertheiner P. Procaine hydrochloride fails to relieve pain in patients with acute pancreatitis. *Digestion*. 2004;69:5–9.
  131. Peiro AM, Martinez J, Martinez E, de Madaria E, Llorens P, Horga JF, et al. Efficacy and tolerance of metamizole versus morphine for acute pancreatitis pain. *Pancreatol*. 2008;8:25–9.
  132. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. *Surg Gynecol Obstet*. 1993;176:480–3.
  133. Sainio V, Kempainen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V, et al. Early antibiotic treatment in acute necrotizing pancreatitis. *Lancet*. 1995;346:663–7.
  134. Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. *Pancreas*. 1996;13:198–201.
  135. Schwarz M, Isenmann R, Meyer H, Beger HG. Antibiotic use in necrotizing pancreatitis. Results of a controlled study. *Dtsch Med Wochenschr*. 1997;122:356–61.
  136. Nordback I, Sand J, Saaristo R, Paajanen H. Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis—a single-center randomized study. *J Gastrointest Surg*. 2001;5:113–8.
  137. Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. *Gastroenterology*. 2004;126:997–1004.
  138. Dellinger EP, Tellado JM, Soto NE, Ashley SW, Barie PS, Dugernier T, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: A randomized, double-blind, placebo-controlled study. *Ann Surg*. 2007;245:674–83.
  139. Røkke O, Harbitz TB, Liljedal J, Pettersen T, Fetvedt T, Heen LØ, et al. Early treatment of severe pancreatitis with imipenem: A prospective randomized clinical trial. *Scand J Gastroenterol*. 2007;42:771–6.
  140. García-Barrasa A, Borobia FG, Pallares R, Jorba R, Poves I, Busquets J, et al. A double-blind, placebo-controlled trial of

- ciprofloxacin prophylaxis in patients with acute necrotizing pancreatitis. *J Gastrointest Surg.* 2009;13:768–74.
141. Xue P, Deng LH, Zhang ZD, Yang XN, Wan MH, Song B, et al. Effect of antibiotic prophylaxis on acute necrotizing pancreatitis: results of a randomized controlled trial. *J Gastroenterol Hepatol.* 2009;24:736–42.
  142. Golub R, Siddiqi F, Pohl D. Role of antibiotics in acute pancreatitis: A meta-analysis. *J Gastrointest Surg.* 1998;2: 496–503.
  143. Sharma VK, Howden CW. Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. *Pancreas.* 2001;22:28–31.
  144. Bassi C, Larvin M, Villatoro E. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. *Cochrane Database Syst Rev.* 2003;CD002941.
  145. Villatoro E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. *Cochrane Database Syst Rev.* 2006;18:CD002941.
  146. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. *Br J Surg.* 2006;93:674–84.
  147. Bai Y, Gao J, Zou D, Li ZS. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. *Am J Gastroenterol.* 2008;103:104–10.
  148. de Vries AC, Besselink MGH, Buskens E, Ridwan BU, Schipper M, van Erpecum KJ, et al. Randomized controlled trials of antibiotic prophylaxis in severe acute pancreatitis: relationship between methodological quality and outcome. *Pancreatol.* 2007;7:531–8.
  149. Xu T, Cai Q. Prophylactic antibiotic treatment in acute necrotizing pancreatitis: results from a meta-analysis. *Scand J Gastroenterol.* 2008;43:1249–58.
  150. Yao L, Huang X, Li Y, Shi R, Zhang G. Prophylactic antibiotics reduce pancreatic necrosis in acute necrotizing pancreatitis: a meta-analysis of randomized trials. *Dig Surg.* 2010;27:442–9.
  151. Villatoro E, Mulla M, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. *Cochrane Database Syst Rev.* 2010;12:CD002941.
  152. Bai Y, Gao J, Zou DW, Li ZS. Antibiotics prophylaxis in acute necrotizing pancreatitis: an update. *Am J Gastroenterol.* 2010;105:705–7.
  153. Wittau M, Mayer B, Scheele J, Henne-Bruns D, Dellinger EP, Isenmann R. Systematic review and meta-analysis of antibiotic prophylaxis in severe acute pancreatitis. *Scand J Gastroenterol.* 2011;46:261–70.
  154. Jiang K, Huang W, Yang XN, Xia Q. Present and future of prophylactic antibiotics for severe acute pancreatitis. *World J Gastroenterol.* 2012;18:279–84.
  155. Craig RM, Dordal E, Myles L. The use of ampicillin in acute pancreatitis. *Ann Intern Med.* 1975;83:831–2.
  156. Finch WT, Sawyers JL, Schenker S. A prospective study to determine the efficacy of antibiotics in acute pancreatitis. *Ann Surg.* 1976;183:667–71.
  157. Howes R, Zuidema GD, Cameron JL. Evaluation of prophylactic antibiotics in acute pancreatitis. *J Surg Res.* 1975;18:197–200.
  158. Buchler M, Malfertheiner P, Friess H, Isenmann R, Vanek E, Grimm H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. *Gastroenterology.* 1992;103:1902–8.
  159. Bertazzoni ME, Benini A, Muner A, Bassi C, Abbas H, Pederzoli P. Pefloxacin penetration into human necrotic pancreatic tissue. *J Antimicrob Chemother.* 1996;38:237–43.
  160. Manes G, Uomo I, Menchise A, Rabitti PG, Ferrara EC, Uomo G. Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. *Am J Gastroenterol.* 2006;101:1348–53.
  161. Maravi-Poma E, Gener J, Alvarez-Lerma F, Olaechea P, Blanco A, Domínguez-Muñoz JE. Spanish Group for the Study of Septic Complications in Severe Acute Pancreatitis. Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: a prospective, randomized, multicenter study comparing two regimens with imipenem-cilastatin. *Intensive Care Med.* 2003;29:1974–80.
  162. Grewe M, Tsiotos GG, Luque de-Leon E, Sarr MG. Fungal infection in acute necrotizing pancreatitis. *J Am Coll Surg.* 1999;188:408–14.
  163. Eggimann P, Jamdar S, Siriwardena AK. Pro/con debate: Antifungal prophylaxis is important to prevent fungal infection in patients with acute necrotizing pancreatitis receiving broad-spectrum antibiotics. *Crit Care.* 2006;10:229.
  164. Shanmugam N, Isenmann R, Barkin JS, Beger HG. Pancreatic fungal infection. *Pancreas.* 2003;27:133–8.
  165. He YM, Lv XS, Ai ZL, Liu ZS, Qian Q, Sun Q, et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. *World J Gastroenterol.* 2003;9:2619–21.
  166. De Waele JJ, Vogelaers D, Blot S, Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. *Clin Infect Dis.* 2003;37:208–13.
  167. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;48:503–35.
  168. Trikudanathan G, Navaneethan U, Vege SS. Intra-abdominal fungal infections complicating acute pancreatitis: a review. *Am J Gastroenterol.* 2011;106:1188–92.
  169. Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, McMahon MJ, et al. Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini Consensus Conference report. *Am J Gastroenterol.* 2011;106:1188–92.
  170. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. *Hepato-gastroenterology.* 2000;47:1147–50.
  171. Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with trasylol: report of a controlled therapeutic trial. *Br Med J.* 1965;2:627–9.
  172. Baden H, Jordal K, Lund F, Zachariae F. A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. *Acta Chir Scand Suppl.* 1967;378:97–102.
  173. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesilate(FOY)in the treatment of acute pancreatitis. *Pancreas.* 1987;2:698–700.
  174. Valderrama R, Perez-Mateo M, Navarro S, Vázquez N, Sanjosé L, Adrián MJ, et al. Multicenter double-blind trial of gabexate mesylate(FOY)in unselected patients with acute pancreatitis. *Digestion.* 1992;51:65–70.
  175. Buchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. *Gastroenterology.* 1993;104: 1165–70.
  176. Freise J, Melzer P, Schmidt FW, Horbach L. Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients. *Z Gastroenterol.* 1986;24:200–11.
  177. Goebell H. Multicenter double-blind study of gabexate mesilate (FOY)given intravenously in low dose in acute pancreatitis. *Digestion.* 1988;40:73.
  178. Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. *Br J Surg.* 1974;61:177–82.
  179. Bachrach WH, Schild PD. A double-blind study of Trasylol in the treatment of pancreatitis. *Ann N Y Acad Sci.* 1968;146:580–92.

180. Ryall RJ. Discussion on acute pancreatitis with a report on a clinical trial of trasylyol. *Anglo Ger Med Rev.* 1966;3:274–83.
181. Möller C, Stjernvall L. Clinical trial with Trasylol against acute pancreatitis. *Ann Chir Gynaecol Fenn.* 1969;58:296–9.
182. Trapnell JE, Talbot CH, Capper WM. Trasylol in acute pancreatitis. *Am J Dig Dis.* 1967;12:409–12.
183. Death from acute pancreatitis. M.R.C. multicentre trial of glucagon and aprotinin. *Lancet.* 1977;2:632–5.
184. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. *Gut.* 1980;21:334–9.
185. Gauthier A, Gillet M, Di Costanzo J, Camelot G, Maurin P, Sarles H. Controlled therapeutic trial of aprotinin and glucagon in acute pancreatitis. *Gastroenterol Clin Biol.* 1978;2:777–84.
186. Seta T, Noguchi Y, Shikata S, Nakayama T. Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis. *BMC Gastroenterol.* 2014;14:102.
187. Sax HC, Warner BW, Talamini MA, Hamilton FN, Bell RH Jr, Fischer JE, et al. Early total parenteral nutrition in acute pancreatitis: lack of beneficial effects. *Am J Surg.* 1987;153:117–24.
188. McClave SA, Greene LM, Snider HL, Makk LJ, Cheadle WG, Owens NA, et al. Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis. *JPEN J Parenter Enteral Nutr.* 1997;21:14–20.
189. Kalfarentzos F, Kehagias J, Mead N, Kokkinis K, Gogos CA. Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomized prospective trial. *Br J Surg.* 1997;84:1665–9.
190. Gupta R, Patel K, Calder PC, Yaqoob P, Primrose JN, Johnson CD. A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II > or =6). *Pancreatol.* 2003;3:406–13.
191. Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. *Dig Surg.* 2006;23:336–44.
192. Windsor AC, Kanwar S, Li AG, Barnes E, Guthrie JA, Spark JJ, et al. Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis. *Gut.* 1998;42:431–5.
193. Abou-Assi S, Craig K, O'Keefe SJ. Hypocaloric jejunal feeding is better than total parenteral nutrition in acute pancreatitis: results of a randomized comparative study. *Am J Gastroenterol.* 2002;97:2255–62.
194. Olah A, Pardavi G, Belagyi T, Nagy A, Issekutz A, Mohamed GE. Early nasojejunal feeding in acute pancreatitis is associated with a lower complication rate. *Nutrition.* 2002;18:259–62.
195. Louie BE, Noseworthy T, Hailey D, Gramlich LM, Jacobs P, Warnock GL. 2004 MacLean-Mueller prize enteral or parenteral nutrition for severe pancreatitis: a randomized controlled trial and health technology assessment. *Can J Surg.* 2005;48:298–306.
196. Eckerwall GE, Axelsson JB, Andersson RG. Early nasogastric feeding in predicted severe acute pancreatitis: A clinical, randomized study. *Ann Surg.* 2006;244:959–65.
197. Marik PE, Zaloga GP. Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis. *BMJ.* 2004;328:1407.
198. Al-Omran M, Groof A, Wilke D. Enteral versus parenteral nutrition for acute pancreatitis. *Cochrane Database Syst Rev.* 2003; CD002837.
199. Li JY, Yu T, Chen GC, Yuan YH, Zhong W, Zhao LN, et al. Enteral nutrition within 48 hours of admission improves clinical outcomes of pancreatitis by reducing complications: a meta-analysis. *PLoS One.* 2013;8:e64926.
200. Sun E, Tharakan M, Kapoor S, Chakravarty R, Salhab A, Buscaglia JM, et al. Poor compliance with ACG guidelines for nutrition and antibiotics in the management of acute pancreatitis: a North American survey of gastrointestinal specialists and primary care physician. *J Pancreas.* 2013;14:221–7.
201. Eatock FC, Chong P, Menezes N, Murray L, McKay CJ, Carter CR, et al. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. *Am J Gastroenterol.* 2005;100:432–9.
202. Petrov MS, Correia MI, Windsor JA. Nasogastric tube feeding in predicted severe acute pancreatitis. A systematic review of the literature to determine safety and tolerance. *J Pancreas.* 2008;9:440–8.
203. Piciocchi M, Merola E, Marignani M, Signoretti M, Valente R, Cocomello L, et al. Nasogastric or nasointestinal feeding in severe acute pancreatitis. *World J Gastroenterol.* 2010;16:3692–6.
204. Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. *Br J Surg.* 2002;89:1103–7.
205. Fuentes-Orozco C, Cervantes-Guevara G, Muciño-Hernández I, López-Ortega A, Ambriz-González G, Gutiérrez-de-la-Rosa JL, et al. L-alanyl-L-glutamine-supplemented parenteral nutrition decreases infectious morbidity rate in patients with severe acute pancreatitis. *JPEN J Parenter Enteral Nutr.* 2008;32:403–11.
206. Wang X, Li W, Li N, Li J. Omega-3 fatty acids-supplemented parenteral nutrition decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: a randomized and controlled study. *JPEN J Parenter Enteral Nutr.* 2008;32:236–41.
207. Pearce CB, Sadek SA, Walters AM, Goggin PM, Somers SS, Toh SK, et al. A double-blind, randomised, controlled trial to study the effects of an enteral feed supplemented with glutamine, arginine, and omega-3 fatty acid in predicted acute severe pancreatitis. *J Pancreas.* 2006;7:361–71.
208. Oláh A, Belágyi T, Pótló L, Romics L Jr, Bengmark S. Symbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. *Hepatogastroenterology.* 2007;54:590–4.
209. Petrov MS, Atduev VA, Zagainov VE. Advanced enteral therapy in acute pancreatitis: is there a room for immunonutrition? A meta-analysis. *Int J Surg.* 2008;6:119–24.
210. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2008;371:651–9.
211. Lévy P, Heresbach D, Pariente EA, Boruchowicz A, Delcenserie R, Millat B, et al. Frequency and risk factors of recurrent pain during refeeding in patients with acute pancreatitis: a multivariate multicentre prospective study of 116 patients. *Gut.* 1997;40:262–6.
212. Chebli JM, Gaburri PD, De Souza AF, Junior EV, Gaburri AK, Felga GE, et al. Oral refeeding in patients with mild acute pancreatitis: prevalence and risk factors of relapsing abdominal pain. *J Gastroenterol Hepatol.* 2005;20:1385–9.
213. Eckerwall GE, Tingstedt BB, Bergenzaun PE, Andersson RG. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery—a randomized clinical study. *Clin Nutr.* 2007;26:758–63.
214. Moraes JM, Felga GE, Chebli LA, Franco MB, Gomes CA, Gaburri PD, et al. A full solid diet as the initial meal in mild acute pancreatitis is safe and result in a shorter length of hospitalization:

- results from a prospective, randomized, controlled, double-blind clinical trial. *J Clin Gastroenterol*. 2010;44:517–22.
215. Stone HH, Fabian TC. Peritoneal dialysis in the treatment of acute alcoholic pancreatitis. *Surg Gynecol Obstet*. 1980;150:878–82.
  216. Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. *Surg Gynecol Obstet*. 1976;143:209–19.
  217. Cooper MJ, Williamson RC, Pollock AV. The role of peritoneal lavage in the prediction and treatment of severe acute pancreatitis. *Ann R Coll Surg Engl*. 1982;64:422–7.
  218. Balldin G, Borgstrom A, Geneil S, Ohlsson K. The effect of peritoneal lavage and aprotinin in the treatment of severe acute pancreatitis. *Res Exp Med*. 1983;183:203–13.
  219. Kivilaakso E, Lempinen M, Mäkeläinen A, Nikki P, Schröder T. Pancreatic resection versus peritoneal lavation for acute fulminant pancreatitis. A randomized prospective study. *Ann Surg*. 1984;199:426–31.
  220. Mayer AD, McMahon MJ, Corfield AP, Cooper MJ, Williamson RC, Dickson AP, et al. Controlled clinical trial of peritoneal lavage for the treatment of severe acute pancreatitis. *N Engl J Med*. 1985;312:399–404.
  221. Ihse I, Evander A, Gustafson I, Holmberg JT. Influence of peritoneal lavage on objective prognostic signs in acute pancreatitis. *Ann Surg*. 1986;204:122–7.
  222. Teerenhovi O, Nordback I, Eskola J. High volume lesser sac lavage in acute necrotizing pancreatitis. *Br J Surg*. 1989;76:370–3.
  223. Ranson JH, Berman RS. Long peritoneal lavage decreases pancreatic sepsis in acute pancreatitis. *Ann Surg*. 1990;211:708–16.
  224. Schröder T, Sainio V, Kivisaari L, Puolakkainen P, Kivilaakso E, Lempinen M. Pancreatic resection versus peritoneal lavage in acute necrotizing pancreatitis. A prospective randomized trial. *Ann Surg*. 1991;214:663–6.
  225. Berling R, Genell S, Ohlsson K. High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: a double-blind randomized multi-center trial. *J Gastroenterol*. 1994;29:479–85.
  226. Zahng HB, Han Y, Wu KC, Ding J, Fan DM, Liu LL, et al. Efficacy of continuous peritoneal lavage for severe acute pancreatitis: a prospective randomized controlled study of 104 cases. *Chin J Pancreatol*. 2007;7:353–6.
  227. Platell C, Cooper D, Hall JC. A meta-analysis of peritoneal lavage for acute pancreatitis. *J Gastroenterol Hepatol*. 2001;16:689–93.
  228. Dong Z, Petrov MS, Xu J, Shanbhag S, Windsor JA, Pang S. Peritoneal lavage for severe acute pancreatitis: a systematic review of randomized trials. *World J Surg*. 2010;34:2103–8.
  229. Pupelis G, Plaudis H, Zeiza K, Drozdova N, Mukans M, Kazaka I. Early continuous veno-venous haemofiltration in the management of severe acute pancreatitis complicated with intra-abdominal hypertension: retrospective review of 10 years' experience. *Ann Intensive Care*. 2012;2:S21.
  230. Xu J, Tian X, Zhang C, Wang M, Li Y. Management of abdominal compartment syndrome in severe acute pancreatitis patients with early continuous veno-venous hemofiltration. *Hepatogastroenterology*. 2013;60:1749–52.
  231. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. *Am J Surg*. 1996;171:394–8.
  232. Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. *Pancreas*. 2004;28:369–73.
  233. Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, et al. Treatment strategy against infection: clinical outcome of continuous regional arterial infusion, enteral nutrition, and surgery in severe acute pancreatitis. *J Gastroenterol*. 2007;42:681–9.
  234. Ino Y, Arita Y, Akashi T, Kimura T, Igarashi H, Oono T, et al. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. *World J Gastroenterol*. 2008;14:6382–7.
  235. Zhou M, Chen B, Sun H, Chen X, Yu Z, Shi H, et al. The efficacy of continuous regional intra-arterial infusion in the treatment of infected pancreatic necrosis. *Pancreatol*. 2013;13:212–5.
  236. Piaścik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J, et al. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic. a randomized controlled study. *Pancreas*. 2010;39:863–7.
  237. Shanbhag ST, Petrov MS, Windsor JA. Is continuous regional arterial infusion of antiproteases now a standard of care in the treatment of acute pancreatitis? *Pancreas*. 2011;40:1141.
  238. Hamada T, Yasunaga H, Nakai Y, Isayama H, Horiguchi H, Matsuda S, et al. Continuous regional arterial infusion for acute pancreatitis: a propensity score analysis using a nationwide administrative database. *Crit Care*. 2013;17:R214.
  239. Neoptolemos JP, Carr-Locke DL, London NJ, Bailey IA, James D, Fossard DP. Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones. *Lancet*. 1988;2:979–83.
  240. Fan ST, Lai EC, Mok FP, Lo CM, Zheng SS, Wong J. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. *N Engl J Med*. 1993;328:228–32.
  241. Nowak A, Nowakowska-Dulawa E, Marek TA, Rybicka J. Final results of the prospective, randomized, controlled study on endoscopic sphincterotomy versus conventional management in acute biliary pancreatitis. *Gastroenterology*. 1995;108:A380.
  242. Fölsch UR, Nitsche R, Lütke R, Hilgers RA, Creutzfeldt W. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The German Study Group on Acute Biliary Pancreatitis. *N Engl J Med*. 1997;336:237–42.
  243. Sharma VK, Howden CW. Meta-analysis of randomized controlled trials of endoscopic retrograde cholangiography and endoscopic sphincterotomy for the treatment of acute biliary pancreatitis. *Am J Gastroenterol*. 1999;94:3211–4.
  244. Kaw M, Al-Antably Y, Kaw P. Management of gallstone pancreatitis: cholecystectomy or ERCP and endoscopic sphincterotomy. *Gastrointest Endosc*. 2002;56:61–5.
  245. Gislason H, Vetrhus M, Horn A, Hoem D, Söndena K, Søreide O, et al. Endoscopic sphincterotomy in acute gallstone pancreatitis: a prospective study of the late outcome. *Eur J Surg*. 2001;167:204–8.
  246. Vázquez-Lglesias JL, González-Conde B, López-Rosés L, Estévez-Prieto E, Alonso-Aguirre P, Lancho A, et al. Endoscopic sphincterotomy for prevention of the recurrence of acute biliary pancreatitis in patients with gallbladder in situ: long-term follow-up of 88 patients. *Surg Endosc*. 2004;18:1442–6.
  247. Bignell M, Dearing M, Hindmarsh A, Rhodes M. ERCP and endoscopic sphincterotomy (ES): a safe and definitive management of gallstone pancreatitis with the gallbladder left in situ. *J Gastrointest Surg*. 2011;15:2205–10.
  248. Targarona EM, Ayuso RM, Bordas JM, Ros E, Pros I, Martínez J, et al. Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bile duct calculi in high-risk patients. *Lancet*. 1996;347:926–9.
  249. Boerma D, Rauws EA, Keulemans YC, Janssen IM, Bolwerk CJ, Timmer R, et al. Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. *Lancet*. 2002;360:761–5.

250. Lau JY, Leow CK, Fung TM, Suen BY, Yu LM, Lai PB, et al. Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients. *Gastroenterology*. 2006;130:96–103.
251. Bakker OJ, van Santvoort HC, Hagenaars JC, Besselink MG, Bollen TL, Gooszen HG, et al. Dutch Pancreatitis Study Group. Timing of cholecystectomy after mild biliary pancreatitis. *Br J Surg*. 2011;98:1446–54.
252. Gloor B, Stahel PF, Müller CA, Worni M, Büchler MW, Uhl W. Incidence and management of biliary pancreatitis in cholecystectomized patients. Results of a 7-year study. *J Gastrointest Surg*. 2003;7:372–7.
253. Trust MD, Sheffield KM, Boyd CA, Benarroch-Gampel J, Zhang D, Townsend CM Jr, et al. Gallstone pancreatitis in older patients: Are we operating enough? *Surgery*. 2011;150:515–25.
254. Nguyen GC, Rosenberg M, Chong RY, Chong CA. Early cholecystectomy and ERCP are associated with reduced readmissions for acute biliary pancreatitis: a nationwide, population-based study. *Gastrointest Endosc*. 2012;75:47–55.
255. Sandzén B, Haapamäki MM, Nilsson E, Stenlund HC, Oman M. Treatment of common bile duct stones in Sweden 1989–2006: an observational nationwide study of a paradigm shift. *World J Surg*. 2012;36:2146–53.
256. Hwang SS, Li BH, Haigh PI. Gallstone pancreatitis without cholecystectomy. *JAMA Surg*. 2013;148:867–72.
257. Castoldi L, De Rai P, Zerbi A, Frulloni L, Uomo G, Gabrielli A, et al. ProInf-AISP (Progetto Informatizzato Pancreatite Acuta, Associazione Italiana per lo Studio del Pancreas) Study Group. Long term outcome of acute pancreatitis in Italy: results of a multicentre study. *Dig Liver Dis*. 2013;45:827–32.
258. Mustafa A, Begaj I, Deakin M, Durkin D, Corless DJ, Wilson R, et al. Long-term effectiveness of cholecystectomy and endoscopic sphincterotomy in the management of gallstone pancreatitis. *Surg Endosc*. 2014;28:127–33.
259. Ranson JH. The timing of biliary surgery in acute pancreatitis. *Ann Surg*. 1979;189:654–63.
260. Frei GJ, Frei VT, Thirlby RC, McClelland RN. Biliary pancreatitis: clinical presentation and surgical management. *Am J Surg*. 1986;151:170–5.
261. DeIorio AV Jr, Vitale GC, Reynolds M, Larson GM. Acute biliary pancreatitis. The roles of laparoscopic cholecystectomy and endoscopic retrograde cholangiopancreatography. *Surg Endosc*. 1995;9:392–6.
262. van Baal MC, Besselink MG, Bakker OJ, van Santvoort HC, Schaapherder AF, Nieuwenhuijs VB, et al. Dutch Pancreatitis Study Group. Timing of cholecystectomy after mild biliary pancreatitis: a systematic review. *Ann Surg*. 2012;255:860–6.
263. Randal Pérez LJ, Fernando Parra J, Aldana DG. The safety of early laparoscopic cholecystectomy (<48 hours) for patients with mild gallstone pancreatitis: a systematic review of the literature and meta-analysis. *Cir Esp*. 2014;92:107–13.
264. Malbrain ML, Cheatham ML, Kirkpatrick A, Sugrue M, Parr M, De Waele J, et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. *Intensive Care Med*. 2006;32:1722–32.
265. Cheatham ML, Malbrain ML, Kirkpatrick A, Sugrue M, Parr M, De Waele J, et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. II. Recommendations. *Intensive Care Med*. 2007;33:951–62.
266. Davis PJ, Eltawil KM, Abu-Wasel B, Walsh MJ, Topp T, Molinari M. Effect of obesity and decompressive laparotomy on mortality in acute pancreatitis requiring intensive care unit admission. *World J Surg*. 2013;37:318–32.
267. De Waele JJ, Hoste E, Blot SI, Decruyenaere J, Colardyn F. Intra-abdominal hypertension in patients with severe acute pancreatitis. *Crit Care*. 2005;9:R452–7.
268. Chen H, Li F, Sun JB, Jia JG. Abdominal compartment syndrome in patients with severe acute pancreatitis in early stage. *World J Gastroenterol*. 2008;14:3541–8.
269. Bezmarevic M, Mirkovic D, Soldatovic I, Stamenkovic D, Mitrovic N, Perisic N, et al. Correlation between procalcitonin and intra-abdominal pressure and their role in prediction of the severity of acute pancreatitis. *Pancreatol*. 2012;12:337–43.
270. Dambrauskas Z, Parseliunas A, Gulbinas A, Pundzius J, Barauskas G. Early recognition of abdominal compartment syndrome in patients with acute pancreatitis. *World J Gastroenterol*. 2009;15:717–21.
271. Bhandari V, Jaipuria J, Singh M, Chawla AS. Intra-abdominal pressure in the early phase of severe acute pancreatitis: canary in a coal mine? Results from a rigorous validation protocol. *Gut Liver*. 2013;7:731–8.
272. Tao J, Wang C, Chen L, Yang Z, Xu Y, Xiong J, et al. Diagnosis and management of severe acute pancreatitis complicated with abdominal compartment syndrome. *J Huazhong Univ Sci Technolog Med Sci*. 2003;23:399–402.
273. Jacob AO, Stewart P, Jacob O. Early surgical intervention in severe acute pancreatitis: Central Australian experience. *ANZ J Surg*. 2014; doi: 10.1111/ans.12707.
274. Mentula P, Hienonen P, Kempainen E, Puolakkainen P, Leppäniemi A. Surgical decompression for abdominal compartment syndrome in severe acute pancreatitis. *Arch Surg*. 2010;145:764–9.
275. Leppäniemi A, Hienonen P, Mentula P, Kempainen E. Subcutaneous linea alba fasciotomy, does it really work? *Am Surg*. 2011;77:99–102.
276. van Brunschot S, Schut AJ, Bouwense SA, Besselink MG, Bakker OJ, van Goor H, et al. Abdominal compartment syndrome in acute pancreatitis: a systematic review. *Pancreas*. 2014;43:665–74.
277. Ke L, Ni HB, Sun JK, Tong ZH, Li WQ, Li N, et al. Risk factors and outcome of intra-abdominal hypertension in patients with severe acute pancreatitis. *World J Surg*. 2012;36:171–8.
278. Holodinsky JK, Roberts DJ, Ball CG, Blaser AR, Starkopf J, Zygun DA, et al. Risk factors for intra-abdominal hypertension and abdominal compartment syndrome among adult intensive care unit patients: a systematic review and meta-analysis. *Crit Care*. 2013;17:R249.
279. Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, et al. Pediatric Guidelines Sub-Committee for the World Society of the Abdominal Compartment Syndrome. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. *Intensive Care Med*. 2013;39:1190–206.
280. Boone B, Zureikat A, Hughes SJ, Moser AJ, Yadav D, Zeh HJ, et al. Abdominal compartment syndrome is an early, lethal complication of acute pancreatitis. *Am Surg*. 2013;79:601–7.
281. Mier J, León EL, Castillo A, Robledo F, Blanco R. Early versus late necrosectomy in severe necrotizing pancreatitis. *Am J Surg*. 1997;173:71–5.
282. Büchler MW, Gloor B, Müller CA, Friess H, Seiler CA, Uhl W. Acute necrotizing pancreatitis: treatment strategy according to the status of infection. *Ann Surg*. 2000;232:619–26.
283. Cirocchi R, Trastulli S, Desiderio J, Boselli C, Parisi A, Noya G, et al. Minimally invasive necrosectomy versus conventional surgery in the treatment of infected pancreatic necrosis: a systematic review and a meta-analysis of comparative studies. *Surg Laparosc Endosc Percutan Tech*. 2013;23:8–20.

284. Mouli VP, Sreenivas V, Garg PK. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: a systematic review and meta-analysis. *Gastroenterology*. 2013;144:333–40.
285. Bradley EL III, Allen K. A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis. *Am J Surg*. 1991;161:19–24.
286. da Costa DW, Boerma D, van Santvoort HC, Horvath KD, Werner J, Carter CR, et al. Staged multidisciplinary step-up management for necrotizing pancreatitis. *Br J Surg*. 2014;101:e65–79.
287. van Santvoort HC, Bakker OJ, Bollen TL, Besselink MG, Ahmed Ali U, Schrijver AM, et al. Dutch Pancreatitis Study Group. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. *Gastroenterology*. 2011;141:1254–63.
288. Sanfey H, Aguilar M, Jones RS. Pseudocysts of the pancreas. a review of 97 cases. *Am Surg*. 1994;60:661–8.
289. Magyar A, Tihanyi T, Szlavik R, Flautner L. Pancreatic pseudocysts causing compression symptoms. *Acta Chir Hung*. 1994;34:59–67.
290. Gardner A, Gardner G, Feller E. Severe colonic complications of pancreatic disease. *J Clin Gastroenterol*. 2003;37:258–62.
291. Barthet M, Lamblin G, Gasmil M, Vitton V, Desjeux A, Grimaud JC. Clinical usefulness of a treatment algorithm for pancreatic pseudocysts. *Gastrointest Endosc*. 2008;67:245–52.
292. Howard TJ, Moore SA, Saxena R, Matthews DE, Schmidt CM, Wiebke EA. Pancreatic duct strictures are a common cause of recurrent pancreatitis after successful management of pancreatic necrosis. *Surgery*. 2004;136:909–16.
293. Connor S, Alexakis N, Raraty MG, Ghaneh P, Evans J, Hughes M, et al. Early and late complications after pancreatic necrosectomy. *Surgery*. 2005;137:499–505.
294. Rau BM, Kempainen EA, Gumbs AA, Büchler MW, Wegscheider K, Bassi C, et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. *Ann Surg*. 2007;245:745–54.
295. Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW. The value of procalcitonin in predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. *Surgery*. 2009;146:72–81.
296. Banks PA, Gerzof SG, Langevin RE, Silverman SG, Sica GT, Hughes MD. CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome. *Int J Pancreatol*. 1995;18:265–70.
297. Rau B, Pralle U, Mayer JM, Beger HG. Role of ultrasonographically guided fine needle aspiration cytology in the diagnosis of infected pancreatic necrosis. *Br J Surg*. 1998;85:179–84.
298. Rodriguez JR, Razo AO, Targarona J, Thayer SP, Rattner DW, Warshaw AL, et al. Debridement and closed packing for sterile or infected necrotizing pancreatitis: insights into indications and outcomes in 167 patients. *Ann Surg*. 2008;247:294–9.
299. van Baal MC, Bollen TL, Bakker OJ, van Goor H, Boermeester MA, Dejong CH, et al. Dutch Pancreatitis Study Group. The role of routine fineneedle aspiration in the diagnosis of infected necrotizing pancreatitis. *Surgery*. 2014;155:442–8.
300. Alsfasser G, Schwandner F, Pertschy A, Hauenstein K, Foitzik T, Klar E. Treatment of necrotizing pancreatitis: redefining the role of surgery. *World J Surg*. 2012;36:1142–7.
301. Besselink MG, Verwer TJ, Schoenmaechers EJ, Buskens E, Ridwan BU, Visser MR, et al. Timing of surgical intervention in necrotizing pancreatitis. *Arch Surg*. 2007;142:1194–201.
302. De Rai P, Zerbi A, Castoldi L, Bassi C, Frulloni L, Uomo G, et al. Surgical management of acute pancreatitis in Italy: lessons from a prospective multicentre study. *HPB (Oxford)*. 2010;12:597–604.
303. van Baal MC, van Santvoort HC, Bollen TL, Bakker OJ, Besselink MG, Gooszen HG. Dutch Pancreatitis Study Group. Systematic review of percutaneous catheter drainage as primary treatment for necrotizing pancreatitis. *Br J Surg*. 2011;98:18–27.
304. van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, et al. Dutch Pancreatitis Study Group. A step-up approach or open necrosectomy for necrotizing pancreatitis. *N Engl J Med*. 2010;362:1491–502.
305. Bakker OJ, van Santvoort HC, van Brunschot S, Geskus RB, Besselink MG, Bollen TL, et al. Dutch Pancreatitis Study Group. Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis. *JAMA*. 2012;307:1053–61.
306. Horvath K, Freeny P, Escallon J, Heagerty P, Comstock B, Glickerman DJ, et al. Safety and efficacy of video-assisted retroperitoneal debridement for infected pancreatic collection. *Arch Surg*. 2010;145:817–25.
307. Bello B, Matthews JB. Minimally invasive treatment of pancreatic necrosis. *World J Gastroenterol*. 2012;18:6829–35.
308. Haghshenas Kashani A, Laurence JM, Kwan V, Johnston E, Hollands MJ, Richardson AJ, et al. Endoscopic necrosectomy of pancreatic necrosis: a systematic review. *Surg Endosc*. 2011;25:3724–30.
309. Raraty HG, Halloran CM, Dodd S, Ghaneh P, Connor S, Evans J, et al. Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach. *Ann Surg*. 2010;251:787–93.
310. Senthil Kumar P, Ravichandran P, Jeswanth S. Case matched comparison study of the necrosectomy by retroperitoneal approach with transperitoneal approach for necrotizing pancreatitis in patients with CT severity score of 7 and above. *Int J Surg*. 2012;10:587–92.
311. Singh P, Das A, Isenberg G, Wong RC, Sivak MV Jr, Agrawal D, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. *Gastrointest Endosc*. 2004;60:544–50.
312. Smithline A, Silverman W, Rogers D, Nisi R, Wiersema M, Jamidar P, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. *Gastrointest Endosc*. 1993;39:652–7.
313. Sherman S, Hawes R, Earle D, Baute P, Bucksot L, Lehman G. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-induced pancreatitis? Randomized prospective study. *Gastrointest Endosc*. 1994;40:124.
314. Tamasky PR, Palesch YY, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. *Gastroenterology*. 1998;115:1518–24.
315. Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. *Gastrointest Endosc*. 2001;54:209–13.
316. Fazel A, Quadri A, Catalano MF, Meyerson SM, Geenen JE. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. *Gastrointest Endosc*. 2003;57:291–4.
317. Patel R, Transky P, Hennessy WS. Does stenting after pancreatic sphincterotomy reduce post-ERCP pancreatitis with prior biliary sphincterotomy? Preliminary results of a prospective randomized controlled trial. *Gastrointest Endosc*. 1999;49:80A.
318. Harewood GC, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. *Gastrointest Endosc*. 2005 Sep;62:367–70.

319. Tsuchiya T, Itoi T, Sofuni A, Itokawa F, Kurihara T, Ishii K, et al. Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial. *J Hepatobiliary Pancreat Surg*. 2007;14:302–7.
320. Sofuni A, Maguchi H, Itoi T, Katanuma A, Hisai H, Niido T, et al. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. *Clin Gastroenterol Hepatol*. 2007;5:1339–46.
321. Ito K, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, et al. Can pancreatic duct stenting prevent post-ERCP pancreatitis in patients who undergo pancreatic duct guidewire placement for achieving selective biliary cannulation? A prospective randomized controlled trial. *J Gastroenterol*. 2010;45:1183–91.
322. Pan XP, Dang T, Meng XM, Xue KC, Chang ZH, Zhang YP. Clinical study on the prevention of post-ERCP pancreatitis by pancreatic duct stenting. *Cell Biochem Biophys*. 2011;61:473–9.
323. Sofuni A, Maguchi H, Mukai T, Kawakami H, Irisawa A, Kubota K, et al. Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. *Clin Gastroenterol Hepatol*. 2011;9:851–8.
324. Kawaguchi Y, Ogawa M, Omata F, Ito H, Shimosegawa T, Mine T. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography. *World J Gastroenterol*. 2012;18:1635–41.
325. Cha SW, Leung WD, Lehman GA, Watkins JL, McHenry L, Fogel EL, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study. *Gastrointest Endosc*. 2013;77:209–16.
326. Lee TH, Moon JH, Choi HJ, Han SH, Cheon YK, Cho YD, et al. Prophylactic temporary 3F pancreatic duct stent to prevent post-ERCP pancreatitis in patients with a difficult biliary cannulation: a multicenter, prospective, randomized study. *Gastrointest Endosc*. 2012;76:578–85.
327. Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. *Endoscopy*. 2010;42:842–53.
328. Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. *Gastrointest Endosc*. 2011;73:275–82.
329. Mazaki T, Mado K, Masuda H, Shiono M. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. *J Gastroenterol*. 2014;49:343–55.
330. Tse F, Yuan Y, Moayyedi P, Leontiadis GI. Guide wire-assisted cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. *Endoscopy*. 2013;45:605–18.
331. Dai HF, Wang XW, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. *Hepatobiliary Pancreat Dis Int*. 2009;8:11–6.
332. Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. *Gut*. 2008;57:1262–7.
333. Zheng MH, Xia HH, Chen YP. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. *Gut*. 2008;57:1632–3.
334. Puig I, Calvet X, Baylina M, Isava Á, Sort P, Llaó J, et al. How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis. *PLoS One*. 2014;9:e92922.
335. Sun HL, Han B, Zhai HP, Cheng XH, Ma K. Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. *Surgeon*. 2014;12:141–7.
336. Sethi S, Sethi N, Wadhwa V, Garud S, Brown A. A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. *Pancreas*. 2014;43:190–7.
337. Foitzik T, Klar E. (Non-)compliance with guidelines for the management of severe acute pancreatitis among German surgeons. *Pancreatol*. 2007;7:80–5.
338. Rebours V, Levy P, Bretagne JF, Bommelaer G, Hammel P, Ruzsiewicz P. Do guidelines influence medical practice? Changes in management of acute pancreatitis 7 years after the publication of the French guidelines. *Eur J Gastroenterol Hepatol*. 2012;24:143–8.
339. McCallum IJ, Hicks GJ, Attwood S, Seymour K. Impact of a care pathway in acute pancreatitis. *Postgrad Med J*. 2011;87:379–81.